{"content":"<li class=\"n-box-item date-title\" data-end=\"1537934399\" data-start=\"1537848000\" data-txt=\"Monday, December 23, 2019\">Tuesday, September 25, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3392944\" data-ts=\"1537916592\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBL\" target=\"_blank\">JBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392944-needham-buy-jabil-on-pull-backs-like-post-earnings-decline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham: Buy Jabil on pull-backs like post-earnings decline</a></h4><ul>   <li>Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>) ended up <font color='red'>down 7.3%</font> today, despite trading up premarket following its <a href=\"https://seekingalpha.com/news/3392701-jabil-plus-3-percent-q4-beats-line-guide\" target=\"_blank\">fiscal Q4 beat</a>.</li>    <li>\"We'd be a buyer on pull-backs,\" Needham says after processing the drop. \"We will continue to see solid momentum in the business, a reiteration for $3.00 in EPS in F19, and attractive valuation.\" Investments in the coming fiscal year will bring down the margin profile in support of new programs, analyst Sean Hannan says. (h/t Bloomberg)</li>    <li>The firm's reiterating a Buy rating and $37 price target, now implying 33% upside after today's decline.</li>    <li><a href=\"https://seekingalpha.com/article/4208100-jabil-inc-2018-q4-results-earnings-call-slides\" target=\"_blank\">Earnings call slides</a></li>   <li><a href=\"https://seekingalpha.com/article/4208225-jabil-inc-jbl-ceo-mark-mondello-q4-2018-results-earnings-call-transcript\" target=\"_blank\">Earnings call transcript</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3392944\" data-linked=\"Needham: Buy Jabil on pull-backs like post-earnings decline\" data-tweet=\"$JBL - Needham: Buy Jabil on pull-backs like post-earnings decline https://seekingalpha.com/news/3392944-needham-buy-jabil-on-pull-backs-like-post-earnings-decline?source=tweet\" data-url=\"https://seekingalpha.com/news/3392944-needham-buy-jabil-on-pull-backs-like-post-earnings-decline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392942\" data-ts=\"1537915492\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYH\" target=\"_blank\">CYH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392942-community-health-unit-to-pay-262m-to-settle-doj-fraud-probe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Community Health unit to pay $262M to settle DoJ fraud probe</a></h4><ul>     <li>Community Health Systems (NYSE:<a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a>)&nbsp;<font color='green'>+3.2%</font> after-hours on news it <a href=\"https://seekingalpha.com/pr/17281052-global-settlement-resolves-u-s-department-justice-investigation-health-management-associates\" target=\"_blank\">reached a settlement</a> ending the U.S. Department of Justice investigation into conduct by Health Management Associates prior to its 2014 acquisition of the hospital operator.</li>     <li>CYH says HMA will pay $262M and an HMA affiliate will plead guilty to one count of conspiracy to commit health care fraud, in resolving claims it defrauded government health care programs and paid doctors kickbacks for patient referrals.</li>     <li>Under the settlement terms, CYH says its existing corporate integrity agreement has been amended and extended by two years, with the amended CIA now running through 2021.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392942\" data-linked=\"Community Health unit to pay $262M to settle DoJ fraud probe\" data-tweet=\"$CYH - Community Health unit to pay $262M to settle DoJ fraud probe https://seekingalpha.com/news/3392942-community-health-unit-to-pay-262m-to-settle-doj-fraud-probe?source=tweet\" data-url=\"https://seekingalpha.com/news/3392942-community-health-unit-to-pay-262m-to-settle-doj-fraud-probe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392941\" data-ts=\"1537914327\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLSN\" target=\"_blank\">NLSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392941-nielsenplus-2_3-on-report-of-interest-from-blackstone-carlyle\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nielsen +2.3% on report of interest from Blackstone, Carlyle</a></h4><ul>   <li>Nielsen Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NLSN' title='Nielsen Holdings N.V.'>NLSN</a>), recently <a href=\"https://seekingalpha.com/news/3389532-reuters-nielsen-exploring-sale-entire-company\" target=\"_blank\">considering an outright sale</a> of the whole company, is <font color='green'>up 2.3%</font> after hours after Bloomberg notes chatter about interest from Blackstone (NYSE:<a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a>) and the Carlyle Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CG' title='The Carlyle Group'>CG</a>).</li>    <li>Nielsen had previously looked at just selling its \"Buy\" segment, focused on purchasing data, but recently has been looking at selling in its entirety -- including the \"Watch\" audience data segment as well.</li>    <li>Activist Elliott Management <a href=\"https://seekingalpha.com/news/3381971-elliott-confirms-active-stake-nielsen-sale-push\" target=\"_blank\">took an 8.4% stake</a> in the company and began pushing for strategic considerations.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3389683-nielsen-plus-5-percent-sale-talks-suntrust-boosts-target\" target=\"_blank\">Nielsen +5% on sale talks; SunTrust boosts target</a> (Sep. 12 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392941\" data-linked=\"Nielsen +2.3% on report of interest from Blackstone, Carlyle\" data-tweet=\"$NLSN $NLSN $BX - Nielsen +2.3% on report of interest from Blackstone, Carlyle https://seekingalpha.com/news/3392941-nielsenplus-2_3-on-report-of-interest-from-blackstone-carlyle?source=tweet\" data-url=\"https://seekingalpha.com/news/3392941-nielsenplus-2_3-on-report-of-interest-from-blackstone-carlyle\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392939\" data-ts=\"1537913458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392939-nike-conference-call-highlights\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike conference call highlights</a></h4><ul> <li>Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>) expects full-year revenue growth be up in the high single digits and gross margin to improve.</li> <li>Tech investments continue to be a big part of the Nike story as management pointed to the \"explosive growth\" in the SNKRS app and benefits of consumer data analysis.</li> <li>CFO update: \"We're off to an even stronger start to the fiscal year than we initially expected. Our currency-neutral growth and profitability is exceeding our expectations. At the same time, global trade uncertainty and geopolitical dynamics have resulted in the dollar strengthening\" and higher foreign exchange costs.\"</li> <li>Shares of Nike are <font color='red'>down 4.1%</font> in AH trading.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3392890-nike-beats-0_04-beats-revenue\" target=\"_blank\">Nike beats by $0.04, beats on revenue</a> (Sept. 25)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392895-nike-posts-strong-sales-growth\" target=\"_blank\">Nike posts strong sales growth again</a> (Sept. 25)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392939\" data-linked=\"Nike conference call highlights\" data-tweet=\"$NKE - Nike conference call highlights https://seekingalpha.com/news/3392939-nike-conference-call-highlights?source=tweet\" data-url=\"https://seekingalpha.com/news/3392939-nike-conference-call-highlights\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392934\" data-ts=\"1537911694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UPL\" target=\"_blank\">UPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392934-ultra-petroleumminus-25-after-failing-to-reach-terms-lenders\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ultra Petroleum -25% after failing to reach terms with lenders</a></h4><ul>     <li>Ultra Petroleum (NASDAQ:<a href='https://seekingalpha.com/symbol/UPL' title='Ultra Petroleum Corp.'>UPL</a>) <font color='red'>-25.3%</font> after-hours following news that it was <a href=\"https://seekingalpha.com/pr/17281019-ultra-petroleum-corp-provides-information-term-loan-discussions-provides-update-semi-annual\" target=\"_blank\">unable to reach agreement</a> with lenders on terms of a senior secured first lien term loan, and says further talks have ceased.</li><li>UPL also says it moved forward the semi-annual redetermination of its borrowing base  under its reserve-based credit facility, which has been reduced by $100M to $1.3B.</li><li>In a <a href=\"https://www.sec.gov/Archives/edgar/data/1022646/000119312518282655/d626939dex991.htm\" target=\"_blank\">lender presentation</a>, UPL says its \"robust\" resource base continues to provide significant coverage for lenders.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392934\" data-linked=\"Ultra Petroleum -25% after failing to reach terms with lenders\" data-tweet=\"$UPL $UPLC - Ultra Petroleum -25% after failing to reach terms with lenders https://seekingalpha.com/news/3392934-ultra-petroleumminus-25-after-failing-to-reach-terms-lenders?source=tweet\" data-url=\"https://seekingalpha.com/news/3392934-ultra-petroleumminus-25-after-failing-to-reach-terms-lenders\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>149&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392933\" data-ts=\"1537911542\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGY\" target=\"_blank\">EGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392933-after-hours-gainers-losers-09-25-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (09/25/2018)</a></h4><ul><li><b>Top Gainers:</b> <a href='https://seekingalpha.com/symbol/EGY' title='VAALCO Energy, Inc.'>EGY</a> <font color='green'>+11.9%</font>. <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+7.8%</font>. <a href='https://seekingalpha.com/symbol/GTS' title='Triple-S Management Corporation'>GTS</a> <font color='green'>+6.6%</font>. <a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a> <font color='green'>+6.4%</font>. <a href='https://seekingalpha.com/symbol/AIR' title='AAR Corporation'>AIR</a>&nbsp;<font color='green'>+4.2%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/GLOP' title='GasLog Partners LP'>GLOP</a> <font color='red'>-5.6%</font>. <a href='https://seekingalpha.com/symbol/TZOO' title='Travelzoo Inc'>TZOO</a> <font color='red'>-5.3%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a>&nbsp;<font color='red'>-5.2%.</font>&nbsp;<a href='https://seekingalpha.com/symbol/CTAS' title='Cintas Corporation'>CTAS</a> <font color='red'>-3.8%</font>. <a href='https://seekingalpha.com/symbol/CLUB' title='Town Sports International Holdings, Inc.'>CLUB</a> <font color='red'>-3.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392933\" data-linked=\"After Hours Gainers / Losers (09/25/2018)\" data-tweet=\"$EGY $EGY $VSTM - After Hours Gainers / Losers (09/25/2018) https://seekingalpha.com/news/3392933-after-hours-gainers-losers-09-25-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392933-after-hours-gainers-losers-09-25-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392929\" data-ts=\"1537910832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INGN\" target=\"_blank\">INGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392929-vanda-pharma-gains-aceto-drops-amid-s-and-p-index-changes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vanda Pharma gains, Aceto drops amid S&amp;P index changes</a></h4><ul>   <li>Vanda Pharmaceuticals is <font color='green'>up 0.7%</font> after hours following word that it's <a href=\"https://www.spice-indices.com/idpfiles/spice-assets/resources/public/documents/786958_rollininvandamotion.pdf?force_download=true\" target=\"_blank\">moving into the S&amp;P SmallCap 600</a>.</li>    <li>The firm is set to replace Inogen (NASDAQ:<a href='https://seekingalpha.com/symbol/INGN' title='Inogen, Inc'>INGN</a>), which is moving up into the MidCap 400. And Inogen is taking the place of Rollins (NYSE:<a href='https://seekingalpha.com/symbol/ROL' title='Rollins Inc.'>ROL</a>), which is moving on up to the S&amp;P 500. Rollins is <font color='red'>off 0.9%</font> after hours.</li>    <li>Rollins' move is to replace Andeavor (NYSE:<a href='https://seekingalpha.com/symbol/ANDV' title='Andeavor'>ANDV</a>), set to be acquired by Marathon Petroleum. All those moves are effective prior to the open of trading on Monday, Oct. 1.</li>    <li>Meanwhile, Garrett Motion (NYSE:<a href='https://seekingalpha.com/symbol/GTX' title='Garrett Motion Inc.'>GTX</a>) -- set to be spun off by Honeywell (NYSE:<a href='https://seekingalpha.com/symbol/HON' title='Honeywell International, Inc.'>HON</a>) -- will take a place in the SmallCap 600 prior to Tuesday's open. It will replace Aceto (NASDAQ:<a href='https://seekingalpha.com/symbol/ACET' title='Aceto Corporation'>ACET</a>), which is ranked near the bottom of the index and isn't representative of the space any more. <a href='https://seekingalpha.com/symbol/ACET' title='Aceto Corporation'>ACET</a> is <font color='red'>down 4.6%</font> postmarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392929\" data-linked=\"Vanda Pharma gains, Aceto drops amid S&amp;P index changes\" data-tweet=\"$INGN $INGN $ROL - Vanda Pharma gains, Aceto drops amid S&amp;P index changes https://seekingalpha.com/news/3392929-vanda-pharma-gains-aceto-drops-amid-s-and-p-index-changes?source=tweet\" data-url=\"https://seekingalpha.com/news/3392929-vanda-pharma-gains-aceto-drops-amid-s-and-p-index-changes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392911\" data-ts=\"1537909409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NITE\" target=\"_blank\">NITE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392911-nightstar-therapeutics-launches-stock-offering-shares-down-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nightstar Therapeutics launches stock offering; shares down 5% after hours</a></h4><ul><li>Nightstar Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NITE' title='Nightstar Therapeutics plc'>NITE</a>) is down&nbsp;<font color='red'>5%</font>&nbsp;after hours on the heels of its announced public offering of 4M American Depositary Shares (ADSs), each representing one ordinary share. Price and terms have yet to be released.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392911\" data-linked=\"Nightstar Therapeutics launches stock offering; shares down 5% after hours\" data-tweet=\"$NITE - Nightstar Therapeutics launches stock offering; shares down 5% after hours https://seekingalpha.com/news/3392911-nightstar-therapeutics-launches-stock-offering-shares-down-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3392911-nightstar-therapeutics-launches-stock-offering-shares-down-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392904\" data-ts=\"1537908411\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DGLY\" target=\"_blank\">DGLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392904-digital-ally-dips-on-announced-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digital Ally dips further on announced share offering</a></h4><ul>    <li>Digital Ally (NASDAQ:<a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a>) has announced a proposed <a href=\"https://seekingalpha.com/pr/17280976-digital-ally-inc-announces-proposed-public-offering-common-stock\" target=\"_blank\">public offering of stock</a>.</li>    <li>It's not mentioned terms but says it expects to grant underwriters a 45-day option to buy up to an additional 15% of shares in the offering.</li>    <li>Roth Capital Partners is represeting underwriters with Aegis serving as co-manager.</li>    <li>Shares are <font color='red'>down 8.5%</font> in light trading after hours, adding on to a day's <font color='red'>decline of 12.4%</font>. As for timing of the offering, shares have <font color='green'>risen 36.5%</font> over the past two weeks.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392904\" data-linked=\"Digital Ally dips further on announced share offering\" data-tweet=\"$DGLY - Digital Ally dips further on announced share offering https://seekingalpha.com/news/3392904-digital-ally-dips-on-announced-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3392904-digital-ally-dips-on-announced-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392900\" data-ts=\"1537907780\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KBH\" target=\"_blank\">KBH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392900-kb-homeplus-4_3-q3-profits-top-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KB Home +4.3% as Q3 profits top expectations</a></h4><ul>   <li>KB Home (NYSE:<a href='https://seekingalpha.com/symbol/KBH' title='KB Home'>KBH</a>) is <font color='green'>up 4.3%</font> after hours following a beat on profits in <a href=\"https://seekingalpha.com/news/3392885-kb-home-beats-0_10-misses-revenue\" target=\"_blank\">fiscal Q3 earnings</a> despite revenues that fell just short of consensus.</li>    <li>Revenues overall grew 7%; deliveries were up 8%, to 2,988 homes, and average selling price was down slightly, to $408,200.</li>    <li>Orders came in ahead of expectations at 2,685 units; net order value of $1.02B, implying an average order price of $379,200.</li>    <li>Backlog was up to 5,484 units (above an expected 5,373) with value of $2.04B.</li>    <li>Homebuilding operating income was $105.6M -- up 38% and beating an expected $102.6M. And housing gross margin was 18%, the top end of of guidance and above expected 17.6%.</li>    <li><a href=\"https://edge.media-server.com/m6/p/kmm6bxpt\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17280907-kb-home-reports-2018-third-quarter-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3392900\" data-linked=\"KB Home +4.3% as Q3 profits top expectations\" data-tweet=\"$KBH - KB Home +4.3% as Q3 profits top expectations https://seekingalpha.com/news/3392900-kb-homeplus-4_3-q3-profits-top-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3392900-kb-homeplus-4_3-q3-profits-top-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392899\" data-ts=\"1537907777\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSTM\" target=\"_blank\">VSTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392899-verastem-up-5-after-hours-on-duvelisib-deal-in-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verastem up 5% after hours on duvelisib deal in China</a></h4><ul><li>Verastem (NASDAQ:<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a>) inks an <a href=\"https://seekingalpha.com/pr/17280941-cspc-pharmaceutical-group-limited-verastem-oncology-sign-exclusive-license-agreement\" target=\"_blank\">agreement </a>with Chinese pharma outfit CSPC Pharmaceutical Group Limited under which the latter will exclusively develop and commercialize COPIKTRA (duvelisib) in China for all indications.</li><li>Under the terms of the deal, Verastem will receive $15M upfront, up to $30M in development milestones, unspecified sales milestones and tiered double-digit royalties on net sales.</li><li>Shares are up&nbsp;<font color='green'>5%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392899\" data-linked=\"Verastem up 5% after hours on duvelisib deal in China\" data-tweet=\"$VSTM - Verastem up 5% after hours on duvelisib deal in China https://seekingalpha.com/news/3392899-verastem-up-5-after-hours-on-duvelisib-deal-in-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3392899-verastem-up-5-after-hours-on-duvelisib-deal-in-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392895\" data-ts=\"1537907279\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392895-nike-posts-strong-sales-growth-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike posts strong sales growth again</a></h4><ul><li>Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>) tops revenue estimates again with its FQ1 report, with a $9.95B tally for the quarter. The North America business generated revenue of $4.15B and the EMEA business churned up $2.61B. Nike saw the Greater China business generate $1.38B (+245 Y/Y).</li> <li>Apparel sales rose 11% during the quarter, while footwear sales increased 10%. Equipment sales were down a percentage point.</li>  <li>The company's gross margin rate came in at 44.2% of sales vs. 44.3% expected and 43.7% a year ago. SG&amp; expenses as a percentage of sales were lower than anticipated.</li> <li>Nike ended the quarter with inventory of $5.22B, +0.3% Y/Y.</li> <li>\"We are delivering stronger global growth and profitability than we anticipated entering this fiscal year,\" noted Nike CFO Andy Campion.</li> <li>Conference call preview: Will Nike offer any granular details on the reported large increase in demand since the Colin Kaepernick deal was announced? The CC is scheduled for 5:00 p.m. ET.</li>  <li>Nike is <font color='red'>down 2.1%</font> in AH trading after running into earnings on +36% YTD tear.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392890-nike-beats-0_04-beats-revenue\" target=\"_blank\">Nike beats by $0.04, beats on revenue</a> (Sept. 25)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3392895\" data-linked=\"Nike posts strong sales growth again\" data-tweet=\"$NKE - Nike posts strong sales growth again https://seekingalpha.com/news/3392895-nike-posts-strong-sales-growth-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3392895-nike-posts-strong-sales-growth-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392891\" data-ts=\"1537906855\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYTU\" target=\"_blank\">AYTU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392891-aytu-bio-sets-terms-for-equity-offering-shares-down-6-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aytu Bio sets terms for equity offering; shares down 6% after hours</a></h4><ul><li>Aytu BioScience (NASDAQ:<a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1385818/000121390018012974/fs12018a1_aytubioscience.htm\" target=\"_blank\">preliminary prospectus</a> for a public offering of 839,695 shares of common stock and warrant to purchase up to the same number shares at a combined price of $2.62/share + warrant.</li><li>On September 8, it filed a <a href=\"https://seekingalpha.com/news/3388901-aytu-bio-readies-equity-offering\" target=\"_blank\">preliminary prospectus</a> for an offering of Class A and Class B units.</li><li>Shares are down&nbsp;<font color='red'>6%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392891\" data-linked=\"Aytu Bio sets terms for equity offering; shares down 6% after hours\" data-tweet=\"$AYTU - Aytu Bio sets terms for equity offering; shares down 6% after hours https://seekingalpha.com/news/3392891-aytu-bio-sets-terms-for-equity-offering-shares-down-6-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3392891-aytu-bio-sets-terms-for-equity-offering-shares-down-6-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392887\" data-ts=\"1537906501\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESNC\" target=\"_blank\">ESNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392887-ensync-misses-0_02-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EnSync misses by $0.02, misses on revenue</a></h4><ul><li>EnSync (NYSEMKT:<a href='https://seekingalpha.com/symbol/ESNC' title='EnSync, Inc.'>ESNC</a>): Q4 GAAP EPS of -$0.07 <span style=\"color:red\">misses by $0.02</span>.</li><li>Revenue of $1.65M (-45.9% Y/Y) <font color='red'>misses by $2.92M</font>.</li><li>Shares <font color='green'>+2.54%</font>.</li><li><a href='https://seekingalpha.com/pr/17280909-ensync-energy-reports-fourth-quarter-fiscal-year-2018-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3392887\" data-linked=\"EnSync misses by $0.02, misses on revenue\" data-tweet=\"$ESNC - EnSync misses by $0.02, misses on revenue https://seekingalpha.com/news/3392887-ensync-misses-0_02-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3392887-ensync-misses-0_02-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392886\" data-ts=\"1537906435\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FND\" target=\"_blank\">FND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392886-weak-read-on-house-prices-sends-floor-decor-and-lumber-liquidators-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weak read on house prices sends Floor &amp; Decor and Lumber Liquidators lower</a></h4><ul><li>Floor &amp; Decor (NYSE:<a href='https://seekingalpha.com/symbol/FND' title='Floor & Decor Holdings, Inc.'>FND</a>)&nbsp;<font color='red'>fell 5.4%</font>&nbsp;and Lumber Liquidators (NYSE:<a href='https://seekingalpha.com/symbol/LL' title='Lumber Liquidators Holdings, Inc.'>LL</a>)&nbsp;<font color='red'>dropped 2.1%</font>&nbsp;after data on housing prices came in weak this morning.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392714-fhfa-housing-price-rises-less-expected\" target=\"_blank\">FHFA Housing Price rises less than expected</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392886\" data-linked=\"Weak read on house prices sends Floor &amp; Decor and Lumber Liquidators lower\" data-tweet=\"$FND $FND $LL - Weak read on house prices sends Floor &amp; Decor and Lumber Liquidators lower https://seekingalpha.com/news/3392886-weak-read-on-house-prices-sends-floor-decor-and-lumber-liquidators-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3392886-weak-read-on-house-prices-sends-floor-decor-and-lumber-liquidators-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392883\" data-ts=\"1537906244\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGIX\" target=\"_blank\">CGIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392883-cancer-genetics-inks-supply-contract-agilent-shares-up-23-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cancer Genetics inks supply contract with Agilent; shares up 23% after hours</a></h4><ul><li>Cancer Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a>) has closed a non-exclusive <a href=\"https://seekingalpha.com/pr/17280873-cancer-genetics-enters-supply-agreement-agilent-technologies\" target=\"_blank\">supply agreement</a> with Agilent Technologies under which the latter will manufacture and supply FISH probe reagents for use in its HPV-Associated Cancer Test &#40;FHACT&#41;.</li><li>The company also plans to out-license the probes both domestically and internationally.</li><li>Shares are up&nbsp;<font color='green'>23%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392883\" data-linked=\"Cancer Genetics inks supply contract with Agilent; shares up 23% after hours\" data-tweet=\"$CGIX - Cancer Genetics inks supply contract with Agilent; shares up 23% after hours https://seekingalpha.com/news/3392883-cancer-genetics-inks-supply-contract-agilent-shares-up-23-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3392883-cancer-genetics-inks-supply-contract-agilent-shares-up-23-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392880\" data-ts=\"1537906036\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ISR\" target=\"_blank\">ISR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392880-isoray-misses-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IsoRay misses by $0.01, beats on revenue</a></h4><ul><li>IsoRay (NYSEMKT:<a href='https://seekingalpha.com/symbol/ISR' title='IsoRay, Inc.'>ISR</a>): Q4 GAAP EPS of -$0.04 <span style=\"color:red\">misses by $0.01</span>.</li><li>Revenue of $1.6M (+16.8% Y/Y) <font color='green'>beats by $0.05M</font>.</li><li>Shares <font color='green'>+2.33%</font>.</li><li><a href='https://seekingalpha.com/pr/17280902-isoray-announces-fourth-quarter-full-year-2018-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3392880\" data-linked=\"IsoRay misses by $0.01, beats on revenue\" data-tweet=\"$ISR - IsoRay misses by $0.01, beats on revenue https://seekingalpha.com/news/3392880-isoray-misses-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3392880-isoray-misses-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392876\" data-ts=\"1537905540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBOW\" target=\"_blank\">SBOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392876-silverbow-resourcesminus-7-after-suntrust-cuts-to-hold-from-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SilverBow Resources -7% after SunTrust cuts to Hold from Buy</a></h4><ul><li>SilverBow Resources (<a href='https://seekingalpha.com/symbol/SBOW' title='SilverBow Resources, Inc.'>SBOW</a> <font color='red'>-6.6%</font>) slumps after SunTrust <a href=\"https://www.streetinsider.com/Analyst+PT+Change/SunTrust+Robinson+Humphrey+Downgrades+SilverBow+Energy+%28SBOW%29+to+Hold/14637000.html\" target=\"_blank\">downgrades</a> shares to Hold from Buy after climbing 6% since Friday.</li><li>SunTrust's Neal Dingmann says even as SBOW has built its portfolio while lowering costs and generating efficiencies over the past few years, the company likely will keep spending on \"less proven, higher cost acreage\" as investors \"remain focused on capital discipline and operating within cash flow,\" holding its leverage at close to 2x.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392876\" data-linked=\"SilverBow Resources -7% after SunTrust cuts to Hold from Buy\" data-tweet=\"$SBOW - SilverBow Resources -7% after SunTrust cuts to Hold from Buy https://seekingalpha.com/news/3392876-silverbow-resourcesminus-7-after-suntrust-cuts-to-hold-from-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3392876-silverbow-resourcesminus-7-after-suntrust-cuts-to-hold-from-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392874\" data-ts=\"1537905073\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFE\" target=\"_blank\">PFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392874-pfizer-facing-difficult-path-to-ramp-up-biosimilar-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pfizer facing difficult path to ramp up biosimilar business</a></h4><ul><li>In an entirely predictable scenario, Pfizer (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='red'>-0.3%</font>) is encountering a broad range of competitive roadblocks in its efforts to gain traction in its biosimilar business, a strategic priority since acquiring Hospira for $17B in 2015.</li><li>Bloomberg <a href=\"https://www.bloomberg.com/news/articles/2018-09-25/brand-name-drugmakers-turn-on-each-other-in-fight-for-new-market?cmpid=socialflow-twitter-business&amp;utm_content=business&amp;utm_source=twitter&amp;utm_medium=social&amp;utm_campaign=socialflow-organic\" target=\"_blank\">reports </a>that Amgen (<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='red'>-0.2%</font>), Johnson &amp; Johnson (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color='red'>-1.2%</font>) and Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a> <font color='green'>+1.2%</font>) have used social media to thwart competitive threats from biosimilars by sowing doubt in patients about the potential risks with switching from branded medicines. Unsurprisingly, branded drug makers have been quick to point out the suffix at the end of biosimilars' active ingredient [e.g., Remicade biosimilar Inflectra (infliximab-dyyb)] implying dissimilarity and higher perceived risk, at least to uninformed patients.</li><li>In another predictable tactic, one that Pfizer (and every other member of Big Pharma) has used for years to protect its banded drug franchises from generic competition, competitors are using exclusionary contracting to maintain their branded businesses. Pfizer has filed litigation against J&amp;J aimed at breaking through contractual barriers.</li><li>As always, the drugs business is a bare knuckle fight.</li><li>Selected tickers: <a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a>, <a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a>, <a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a>, <a href='https://seekingalpha.com/symbol/XPH' title='SPDR S&P Pharmaceuticals ETF'>XPH</a>, <a href='https://seekingalpha.com/symbol/IHE' title='iShares U.S. Pharmaceuticals ETF'>IHE</a>, <a href='https://seekingalpha.com/symbol/PPH' title='VanEck Vectors Pharmaceutical ETF'>PPH</a>, <a href='https://seekingalpha.com/symbol/VHT' title='Vanguard Health Care ETF'>VHT</a>, <a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>, <a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>, <a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>, <a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>, <a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a>, <a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>, <a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>, <a href='https://seekingalpha.com/symbol/BHC' title='Bausch Health Companies Inc.'>BHC</a>, <a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>, <a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>, <a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>, <a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>, TKPYY, <a href='https://seekingalpha.com/symbol/ESRX' title='Express Scripts, Inc.'>ESRX</a>, <a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>, <a href='https://seekingalpha.com/symbol/CVS' title='CVS Health Corporation'>CVS</a>, <a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a>, <a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3392874\" data-linked=\"Pfizer facing difficult path to ramp up biosimilar business\" data-tweet=\"$PFE $PFE $AMGN - Pfizer facing difficult path to ramp up biosimilar business https://seekingalpha.com/news/3392874-pfizer-facing-difficult-path-to-ramp-up-biosimilar-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3392874-pfizer-facing-difficult-path-to-ramp-up-biosimilar-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392872\" data-ts=\"1537904797\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOT\" target=\"_blank\">TOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392872-total-reiterates-key-targets-accelerates-2018-share-buyback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Total reiterates key targets, accelerates 2018 share buyback</a></h4><ul>     <li>Total (<a href='https://seekingalpha.com/symbol/TOT' title='TOTAL S.A.'>TOT</a> <font color='green'>+1.6%</font>) says it is <a href=\"https://www.reuters.com/article/us-total-investors/french-oil-major-total-stands-by-targets-accelerates-2018-share-buyback-idUSKCN1M52E7\" target=\"_blank\">sticking with key targets</a> for production, savings and investments for the coming years, and pledges to buy back $1.5B of shares by the end of this year after purchasing $600M in shares during H1 as part of its $5B 2018-20 buyback program announced in February.</li>     <li>With Brent oil prices at $60/bbl, TOT expects cash flow to rise by $7B during 2017-20 and return on equity to increase to 12%, which will enable it to continue to reward shareholders.</li>     <li>TOT keeps its production growth target of 6%-7%/year during 2017-20 and capital investments for the same period at $15B-$17B, while also maintaining its cost savings target of $5B/year by 2020 compared to the 2014 base.</li>     <li>Separately, TOT <a href=\"https://www.ogj.com/articles/2018/09/total-increases-share-in-danish-underground-consortium.html\" target=\"_blank\">agrees to acquire</a> all of Chevron&rsquo;s (<a href='https://seekingalpha.com/symbol/CVX' title='Chevron Corporation'>CVX</a> <font color='green'>+0.7%</font>) share capital in the Danish Underground Consortium, which will increase its stake in the project and expand its North Sea presence.</li><li>The purchase will increase TOT&rsquo;s  operated share of DUC to 43.2%, where partners include Royal Dutch Shell with 36.8%; the consortium, which  started production in 1972, operates 15 fields in the Central Graben  area of the North Sea and covers nearly 90% of Danish oil and gas  production, which totaled 182K boe/day in 2017.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392872\" data-linked=\"Total reiterates key targets, accelerates 2018 share buyback\" data-tweet=\"$TOT $TOT $CVX - Total reiterates key targets, accelerates 2018 share buyback https://seekingalpha.com/news/3392872-total-reiterates-key-targets-accelerates-2018-share-buyback?source=tweet\" data-url=\"https://seekingalpha.com/news/3392872-total-reiterates-key-targets-accelerates-2018-share-buyback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392870\" data-ts=\"1537903994\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NRE\" target=\"_blank\">NRE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392870-northstar-realtyplus-4_8-after-investor-suggests-selling-assets-going-private\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northstar Realty +4.8% after investor suggests selling assets or going private</a></h4><ul><li>Northstar Realty Europe (NYSE:<a href='https://seekingalpha.com/symbol/NRE' title='NorthStar Realty Europe Corp.'>NRE</a>)<font color='green'> jumps 4.8%</font>&nbsp;after an<a href=\"https://seekingalpha.com/filing/4178554\" target=\"_blank\"> investor suggests</a> the company either sell all of its assets piecemeal or go private.</li><li>Late Monday, Senvest Management filed with the SEC changing its status to an activist investor from passive and included a letter to NorthStar Realty Europe's board in the filing.</li><li>Main takeaways from the letter: Senvest thinks the main reason for NRE trading at a significant discount to net asset value is the management fees it pays to Colony Capital (<a href='https://seekingalpha.com/symbol/CLNY' title='Colony Capital, Inc.'>CLNY</a> <font color='green'>+0.3%</font>), its external manager.</li><li>NRE should sell assets to institutional investors and return the proceeds to shareholders, or</li><li>Colony Capital should take the company private \"at a price at or above the aggregate price that would be received in asset sales and which should represent a valuation close to or potentially greater than NAV,\" Senvest Management said in the letter.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3379332-northstar-realty-europe-plus-2_6-percent-premarket-q2-posts-earning-vs-year-ago-loss\" target=\"_blank\">NorthStar Realty Europe +2.6% premarket as Q2 posts earning vs year-ago loss</a> (Aug. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392870\" data-linked=\"Northstar Realty +4.8% after investor suggests selling assets or going private\" data-tweet=\"$NRE $NRE $CLNY - Northstar Realty +4.8% after investor suggests selling assets or going private https://seekingalpha.com/news/3392870-northstar-realtyplus-4_8-after-investor-suggests-selling-assets-going-private?source=tweet\" data-url=\"https://seekingalpha.com/news/3392870-northstar-realtyplus-4_8-after-investor-suggests-selling-assets-going-private\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392869\" data-ts=\"1537903259\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTI\" target=\"_blank\">WTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392869-w-and-t-offshore-gulf-of-mexico-exploration-well-tops-pre-drill-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">W&amp;T Offshore Gulf of Mexico exploration well tops pre-drill estimates</a></h4><ul>     <li>W&amp;T Offshore (<a href='https://seekingalpha.com/symbol/WTI' title='W&T Offshore, Inc.'>WTI</a> <font color='green'>+9.4%</font>) shoots higher after an exploration well drilled in the Ewing Bank 910 field in deepwater Gulf of Mexico <a href=\"https://www.ogj.com/articles/2018/09/w-t-to-spud-second-exploration-well-in-ewing-bank-910-field.html\" target=\"_blank\">exceeded pre-drill estimates</a> by logging 163 ft. of net pay.</li><li>WTI expects to have the well on  production via existing infrastructure before year-end 2018.</li><li>Following its completion, the rig will spud a second well, which the company says is another low-risk exploration opportunity in the field.</li><li>WTI says both wells are part of a drilling joint venture program for the  development of 14 pre-identified projects in the Gulf of Mexico, four of which are  underway or on production.</li><li><a href=\"https://seekingalpha.com/news/3392638-w-and-t-offshore-sell-non-core-asset\" target=\"_blank\">Earlier</a>: W&amp;T&nbsp;Offshore to sell non-core asset (Sep. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392869\" data-linked=\"W&amp;T Offshore Gulf of Mexico exploration well tops pre-drill estimates\" data-tweet=\"$WTI - W&amp;T Offshore Gulf of Mexico exploration well tops pre-drill estimates https://seekingalpha.com/news/3392869-w-and-t-offshore-gulf-of-mexico-exploration-well-tops-pre-drill-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3392869-w-and-t-offshore-gulf-of-mexico-exploration-well-tops-pre-drill-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392868\" data-ts=\"1537903129\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NPTN\" target=\"_blank\">NPTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392868-neophotonicsplus-6_5-needham-lauding-product-advantages\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeoPhotonics +6.5% with Needham lauding product advantages</a></h4><ul>   <li>NeoPhotonics (NYSE:<a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a>) is <font color='green'>up 6.5%</font> and at a three-week high as Needham praises a refreshed product line giving the company a jump a competition.</li>    <li>The company gets a \"substantial technological advantage\" from being first to market for critical 400G, 600G and 1.2 TB components, analyst Alex Henderson says, and it's seeing uptake for the components from its large customers, positioning the company for sustained growth and profitability. (h/t Bloomberg)</li>    <li>Henderson has a Strong Buy on the shares and a price target of $12, implying 45% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392868\" data-linked=\"NeoPhotonics +6.5% with Needham lauding product advantages\" data-tweet=\"$NPTN - NeoPhotonics +6.5% with Needham lauding product advantages https://seekingalpha.com/news/3392868-neophotonicsplus-6_5-needham-lauding-product-advantages?source=tweet\" data-url=\"https://seekingalpha.com/news/3392868-neophotonicsplus-6_5-needham-lauding-product-advantages\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392863\" data-ts=\"1537901802\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCC\" target=\"_blank\">OCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392863-technology-top-5-gainers-losers-of-2_55-pm-09-25-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 2.55 PM (09/25/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/OCC' title='Optical Cable Corporation'>OCC</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/TRT' title='Trio-Tech International'>TRT</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/FTNW' title='FTE Networks, Inc.'>FTNW</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='green'>+11%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/AWSM' title='Cool Holdings Inc.'>AWSM</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/DQ' title='DAQO New Energy Corp.'>DQ</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a> <font color='red'>-8%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3392863\" data-linked=\"Technology - Top 5 Gainers / Losers as of 2.55 PM (09/25/2018)\" data-tweet=\"$OCC $OCC $TRT - Technology - Top 5 Gainers / Losers as of 2.55 PM (09/25/2018) https://seekingalpha.com/news/3392863-technology-top-5-gainers-losers-of-2_55-pm-09-25-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392863-technology-top-5-gainers-losers-of-2_55-pm-09-25-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392861\" data-ts=\"1537901298\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AET\" target=\"_blank\">AET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392861-new-york-regulator-concerns-on-cvs-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New York regulator has concerns on CVS deal</a></h4><ul><li>The letter from NY Dept. of Financial Services chief Maria Vullo was sent last week to the Connecticut Insurance Dept.'s Katherine Wade. A hearing on the merger in Connecticut is set for Oct. 4.</li><li>In the letter, Vullo says the deal would have the two players with \"incredibly\" large market share, and create \"real concerns\" on pricing power.</li><li>Aetna (<a href='https://seekingalpha.com/symbol/AET' title='Aetna, Inc.'>AET</a> <font color='red'>-1.5%</font>), CVS (<a href='https://seekingalpha.com/symbol/CVS' title='CVS Health Corporation'>CVS</a> <font color='red'>-1.6%</font>)</li><li>The Cigna (<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a> <font color='red'>-1.4%</font>)/Express Scripts (<a href='https://seekingalpha.com/symbol/ESRX' title='Express Scripts, Inc.'>ESRX</a> <font color='red'>-0.9%</font>) deal is also undergoing state reviews.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392861\" data-linked=\"New York regulator has concerns on CVS deal\" data-tweet=\"$AET $AET $CVS - New York regulator has concerns on CVS deal https://seekingalpha.com/news/3392861-new-york-regulator-concerns-on-cvs-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3392861-new-york-regulator-concerns-on-cvs-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392859\" data-ts=\"1537900428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DTEA\" target=\"_blank\">DTEA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392859-large-davidstea-stakeholder-lightend-load\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Large DavidsTea stakeholder lightend load</a></h4><ul> <li>TDM Asset Management announces that it disposed of 579,902 shares of DavidsTea (<a href='https://seekingalpha.com/symbol/DTEA' title='DAVIDs TEA'>DTEA</a> <font color='red'>-2.1%</font>) on September 20.</li> <li>TDM has disposed of 2.74M shares of DTEA&nbsp;since its last Form 62-103F1 filing on June 15.</li>  <li>The securities were disposed of in multiple trades on the NASDAQ exchange at an average price of $3.43 per share for an aggregate sale price of $9,377,870.</li> <li>The recent disposition actions decreases TDM's position in DavidsTea to approximately a stake of 1.6%.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17280545-tdm-asset-management-pty-ltd-disposes-securities-davidstea-nasdaq-dtea\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3392859\" data-linked=\"Large DavidsTea stakeholder lightend load\" data-tweet=\"$DTEA - Large DavidsTea stakeholder lightend load https://seekingalpha.com/news/3392859-large-davidstea-stakeholder-lightend-load?source=tweet\" data-url=\"https://seekingalpha.com/news/3392859-large-davidstea-stakeholder-lightend-load\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392857\" data-ts=\"1537900174\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SO\" target=\"_blank\">SO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392857-fate-of-vogtle-nuclear-project-down-to-game-of-chicken\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fate of Vogtle nuclear project down to &#39;game of chicken&#39;</a></h4><ul>     <li>&ldquo;It appears that something like a <a href=\"https://finance.yahoo.com/news/fate-28-billion-u-nuclear-161007790.html\" target=\"_blank\">game of chicken could be under way</a>,&rdquo; says Glenrock Associates analyst Paul Patterson, referring to the fate of the only nuclear power plant under construction in the U.S.</li>     <li>Southern Co. (<a href='https://seekingalpha.com/symbol/SO' title='Southern Company'>SO</a> <font color='red'>-2.1%</font>) and one of its minority partners in the $27B Vogtle project in Georgia are squaring off ahead of a deadline this afternoon, as 30% stakeholder Oglethorpe Power <a href=\"https://seekingalpha.com/news/3392604-owners-georgia-nuke-plant-delay-vote-one-seeks-cost-conditions\" target=\"_blank\">said last night</a> that it would continue with the effort to build the project only if costs were capped - a condition SO rejects.</li>     <li>\"Oglethorpe Power is using the vote to try to burden others with its obligations and extract unreasonable concessions,\" SO says, warning that a \"no\" vote by Oglethorpe <a href=\"https://seekingalpha.com/pr/17279281-three-vogtle-3-and-4-co-owners-voted-move-forward-construction\" target=\"_blank\">would force the project to be canceled</a>.</li>     <li>In response, Oglethorpe says it is &ldquo;far from being obstructionist to the project as evidenced by the fact we would be willing to shoulder our burden of the $2.3B overrun, which includes an $800M contingency.\"</li>     <li>SO&rsquo;s Georgia Power utility disclosed in August that Vogtle's costs had increased by another $2.3B, nearly double the original estimate; the Municipal Electric Authority of Georgia and Dalton Utilities, the other minority partners, have agreed to move forward.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392857\" data-linked=\"Fate of Vogtle nuclear project down to &#39;game of chicken&#39;\" data-tweet=\"$SO - Fate of Vogtle nuclear project down to &#39;game of chicken&#39; https://seekingalpha.com/news/3392857-fate-of-vogtle-nuclear-project-down-to-game-of-chicken?source=tweet\" data-url=\"https://seekingalpha.com/news/3392857-fate-of-vogtle-nuclear-project-down-to-game-of-chicken\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392852\" data-ts=\"1537898497\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PGLC\" target=\"_blank\">PGLC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392852-energy-materials-top-gainers-losers-of-2-00-pm-09-25-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials  - Top Gainers / Losers as of 2:00 PM (09/25/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PGLC' title='Pershing Gold Corporation'>PGLC</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/DRD' title='DRDGOLD Limited'>DRD</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/BAS' title='Basic Energy Services, Inc.'>BAS</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ANW' title='Aegean Marine Petroleum Network Inc.'>OTC:ANW</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='red'>-49%</font>. <a href='https://seekingalpha.com/symbol/TGC' title='Tengasco, Inc'>TGC</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='red'>-18%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392852\" data-linked=\"Energy/Materials  - Top Gainers / Losers as of 2:00 PM (09/25/2018)\" data-tweet=\"$PGLC $PGLC $DRD - Energy/Materials - Top Gainers / Losers as of 2:00 PM (09/25/2018) https://seekingalpha.com/news/3392852-energy-materials-top-gainers-losers-of-2-00-pm-09-25-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392852-energy-materials-top-gainers-losers-of-2-00-pm-09-25-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392851\" data-ts=\"1537898373\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHRS\" target=\"_blank\">CHRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392851-coherus-bios-neulasta-biosimilar-okd-in-europe-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coherus Bio&#39;s Neulasta biosimilar OK&#39;d in Europe; shares up 6%</a></h4><ul><li>The European Commission &#40;EC&#41;&nbsp;<a href=\"https://seekingalpha.com/pr/17280740-coherus-biosciences-receives-european-commission-approval-udenyca-pegfilgrastim-biosimilar\" target=\"_blank\">approves </a>Coherus BioSciences' (<a href='https://seekingalpha.com/symbol/CHRS' title='Coherus BioSciences'>CHRS</a> <font color='green'>+5.9%</font>) UDENYCA (pegfilgrastim-cbqv), a biosimilar of Amgen's (<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='green'>+0.3%</font>) Neulasta.</li><li>The company's U.S. marketing application is currently under FDA review with an action date of November 3.</li><li>The advisory group CHMP gave its thumbs up for Mylan's Neulasta biosimilar Fulphila last week. A final decision from the EC should be announced in Q4. The FDA approved it about four months ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3361547-fda-oks-mylans-neulasta-biosimilar-shares-5-percent-hours\" target=\"_blank\">FDA OKs Mylan's Neulasta biosimilar; shares up 5% after hours</a> (June 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392851\" data-linked=\"Coherus Bio&#39;s Neulasta biosimilar OK&#39;d in Europe; shares up 6%\" data-tweet=\"$CHRS $CHRS $AMGN - Coherus Bio&#39;s Neulasta biosimilar OK&#39;d in Europe; shares up 6% https://seekingalpha.com/news/3392851-coherus-bios-neulasta-biosimilar-okd-in-europe-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3392851-coherus-bios-neulasta-biosimilar-okd-in-europe-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392844\" data-ts=\"1537896578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHOP\" target=\"_blank\">SHOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392844-shopify-volatile-after-ceo-mentions-amazon-threat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shopify volatile after CEO mentions Amazon threat</a></h4><ul><li>Shopify (<a href='https://seekingalpha.com/symbol/SHOP' title='Shopify'>SHOP</a> <font color='green'>+0.7%</font>) dropped sharply before quickly tracking back up again following comments by CEO Tobias Lutke about Amazon encroaching on its turf.</li><li>Lutke made the comments in an interview with Bloomberg TV.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392844\" data-linked=\"Shopify volatile after CEO mentions Amazon threat\" data-tweet=\"$SHOP - Shopify volatile after CEO mentions Amazon threat https://seekingalpha.com/news/3392844-shopify-volatile-after-ceo-mentions-amazon-threat?source=tweet\" data-url=\"https://seekingalpha.com/news/3392844-shopify-volatile-after-ceo-mentions-amazon-threat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392837\" data-ts=\"1537895035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCCY\" target=\"_blank\">FCCY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392837-financials-top-5-gainers-losers-of-1-03-pm-09-25-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:03 PM (09/25/2018)</a></h4><ul><li><b>Gainers:&nbsp;&nbsp;</b><a href='https://seekingalpha.com/symbol/FCCY' title='1st Constitution Bancorp &#40;NJ&#41;'>FCCY</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/ONDK' title='OnDeck Capital'>ONDK</a> <font color='green'>+5%</font>.</li><li><b>Losers: </b><a href='https://seekingalpha.com/symbol/FPAY' title='FlexShopper, Inc.'>FPAY</a> <font color='red'>-29%</font>. <a href='https://seekingalpha.com/symbol/AINC' title='Ashford Inc.'>AINC</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/GSHD' title='Goosehead Insurance'>GSHD</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392837\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:03 PM (09/25/2018)\" data-tweet=\"$FCCY $FCCY $ONDK - Financials - Top 5 Gainers / Losers as of 1:03 PM (09/25/2018) https://seekingalpha.com/news/3392837-financials-top-5-gainers-losers-of-1-03-pm-09-25-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392837-financials-top-5-gainers-losers-of-1-03-pm-09-25-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392834\" data-ts=\"1537894672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QHC\" target=\"_blank\">QHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392834-quorum-up-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Quorum up 15%</a></h4><ul><li>Thinly traded micro cap Quorum Health (<a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a> <font color='green'>+15.1%</font>) perks up on more than triple normal volume, albeit on turnover of only 851K shares.</li><li>No particular news accounts for the action.</li><li>At end of June, it had only $2.8M in cash while accounts receivable totaled over $327M. Cash flow from operations was $17.2M in Q2 and $14.6M in H1.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392834\" data-linked=\"Quorum up 15%\" data-tweet=\"$QHC - Quorum up 15% https://seekingalpha.com/news/3392834-quorum-up-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3392834-quorum-up-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392833\" data-ts=\"1537894425\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDRY\" target=\"_blank\">EDRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392833-midday-gainers-losers-09-25-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (09/25/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/EDRY' title='EuroDry Ltd.'>EDRY</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/OASM' title='Oasmia Pharmaceutical'>OASM</a> <font color='green'>+32%</font>. <a href='https://seekingalpha.com/symbol/XOXO' title='XO Group Inc.'>XOXO</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/AGTC' title='Applied Genetic Technologies Corporation'>AGTC</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/OXFD' title='Oxford Immunotec Global PLC'>OXFD</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/SONC' title='Sonic Corp.'>SONC</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/TRT' title='Trio-Tech International'>TRT</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/ALRN' title='Aileron Therapeutics'>ALRN</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color='green'>+15%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='red'>-47%</font>. <a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a> <font color='red'>-37%</font>. <a href='https://seekingalpha.com/symbol/FPAY' title='FlexShopper, Inc.'>FPAY</a> <font color='red'>-30%</font>. <a href='https://seekingalpha.com/symbol/DCTH' title='Delcath Systems, Inc.'>OTC:DCTH</a> <font color='red'>-25%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/TGC' title='Tengasco, Inc'>TGC</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/CKPT' title='CHECKPOINT THERAPEUTICS'>CKPT</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/AWSM' title='Cool Holdings Inc.'>AWSM</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/TMSR' title='TMSR Holding Co., Ltd.'>TMSR</a> <font color='red'>-19%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3392833\" data-linked=\"Midday Gainers / Losers (09/25/2018)\" data-tweet=\"$EDRY $EDRY $OASM - Midday Gainers / Losers (09/25/2018) https://seekingalpha.com/news/3392833-midday-gainers-losers-09-25-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392833-midday-gainers-losers-09-25-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392831\" data-ts=\"1537893931\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSK\" target=\"_blank\">GSK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392831-glaxos-tb-vaccine-shows-positive-effect-in-mid-stage-study-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Glaxo&#39;s TB vaccine shows positive effect in mid-stage study; shares up 1%</a></h4><ul><li>GlaxoSmithKline (<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a> <font color='green'>+0.8%</font>) and development partner Aeras <a href=\"https://www.gsk.com/en-gb/media/press-releases/gsk-candidate-vaccine-helps-prevent-active-pulmonary-tuberculosis-in-hiv-negative-adults-in-phase-ii-study/\" target=\"_blank\">announce </a>positive preliminary results from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT01755598?term=NCT01755598&amp;rank=2\" target=\"_blank\">Phase 2b clinical trial </a>evaluating GSK's M72/AS01E tuberculosis &#40;TB&#41; vaccine candidate in HIV-negative adults with latent tuberculosis infection in Kenya, South Africa and Zambia.</li><li>Participants (n=3,573) received two doses of either M72/AS01E or placebo 30 days apart and followed for two years. The overall efficacy rate was 54%. In the vaccine group, 10 subjects developed active pulmonary tuberculosis versus 22 in the control group.</li><li>The results were just published in the <em>New England Journal of Medicine</em>.</li><li>The study is ongoing. Three-year follow-up data will be reported in 2019.</li><li>99% of participants consented to enter the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02097095?term=NCT02097095&amp;rank=1\" target=\"_blank\">biobanking study</a> sponsored by Aeras. The collected samples will enable researchers to further investigate the mechanisms of protection and the potential identification of biomarkers that may indicate a higher risk of developing TB disease.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392831\" data-linked=\"Glaxo&#39;s TB vaccine shows positive effect in mid-stage study; shares up 1%\" data-tweet=\"$GSK - Glaxo&#39;s TB vaccine shows positive effect in mid-stage study; shares up 1% https://seekingalpha.com/news/3392831-glaxos-tb-vaccine-shows-positive-effect-in-mid-stage-study-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3392831-glaxos-tb-vaccine-shows-positive-effect-in-mid-stage-study-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392830\" data-ts=\"1537893863\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQ\" target=\"_blank\">SQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392830-square-talks-new-payroll-app\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Square talks new payroll app</a></h4><ul><li>Square (<a href='https://seekingalpha.com/symbol/SQ' title='Square, Inc.'>SQ</a> <font color='green'>+7%</font>) announces the Square Payroll App for employers.</li><li><a href=\"https://squareup.com/townsquare/how-square-payroll-app-helps-businesses\" target=\"_blank\">Blog post</a></li><li>ADP (<a href='https://seekingalpha.com/symbol/ADP' title='Automatic Data Processing, Inc.'>ADP</a> <font color='red'>-1%</font>) and Paychex (<a href='https://seekingalpha.com/symbol/PAYX' title='Paychex, Inc.'>PAYX</a> <font color='red'>-1.6%</font>) are giving up some ground. Other names of interest: Intuit (<a href='https://seekingalpha.com/symbol/INTU' title='Intuit Inc.'>INTU</a> <font color='green'>+0.5%</font>), Workday (<a href='https://seekingalpha.com/symbol/WDAY' title='Workday'>WDAY</a> <font color='green'>+1.9%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392830\" data-linked=\"Square talks new payroll app\" data-tweet=\"$SQ $SQ $ADP - Square talks new payroll app https://seekingalpha.com/news/3392830-square-talks-new-payroll-app?source=tweet\" data-url=\"https://seekingalpha.com/news/3392830-square-talks-new-payroll-app\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392829\" data-ts=\"1537893639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392829-ge-turbine-halted-edf-plant-in-france-following-u-s-shutdowns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE turbine halted at EDF plant in France following U.S. shutdowns</a></h4><ul>     <li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='red'>-2.6%</font>) shares slide deeper into the red after French power utility EDF (<a href='https://seekingalpha.com/symbol/ECIFF' title='Electricite de France SA'>OTCPK:ECIFF</a>, <a href='https://seekingalpha.com/symbol/ECIFY' title='Electricite de France SA ADR'>OTCPK:ECIFY</a>) says it <a href=\"https://www.reuters.com/article/us-ge-power-edf/frances-edf-halts-ge-turbine-at-bouchain-following-u-s-shutdowns-idUSKCN1M5280\" target=\"_blank\">shut down a GE turbine</a> at its Bouchain power plant for a month due to a turbine blade issue that has shut down similar plants in the U.S.</li>     <li>EDF says it took the action over the weekend after GE said <a href=\"https://seekingalpha.com/news/3391847-reuters-ge-says-four-u-s-power-turbines-shut-due-blade-problem\" target=\"_blank\">last week</a> it had halted four of its turbines at Exelon facilities in Texas when one of them suffered a blade failure.</li>     <li>&ldquo;The [Bouchain] plant will be closed until Oct. 22 to proceed with controls and maintenance as advised by GE,\" EDF says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392829\" data-linked=\"GE turbine halted at EDF plant in France following U.S. shutdowns\" data-tweet=\"$GE $GE $ECIFF - GE turbine halted at EDF plant in France following U.S. shutdowns https://seekingalpha.com/news/3392829-ge-turbine-halted-edf-plant-in-france-following-u-s-shutdowns?source=tweet\" data-url=\"https://seekingalpha.com/news/3392829-ge-turbine-halted-edf-plant-in-france-following-u-s-shutdowns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>71&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392816\" data-ts=\"1537892548\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEOG\" target=\"_blank\">NEOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392816-neogen-q1-miss-pressures-shares-down-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neogen Q1 miss pressures shares, down 15%</a></h4><ul><li>Thinly traded Neogen (<a href='https://seekingalpha.com/symbol/NEOG' title='Neogen Corporation'>NEOG</a> <font color='red'>-14.9%</font>) slumps on triple normal volume, albeit on turnover of only 561K shares, following its <a href=\"https://seekingalpha.com/pr/17279971-neogen-reports-first-quarter-results\" target=\"_blank\">Q1 results</a> that missed revenue consensus by $4.8M.</li><li>Revenues were up 6% to ~$99.6M, modestly constrained by a $1M hit due to reclassifications of COGS and operating expenses related to a new revenue recognition standard.</li><li>Gross margin tightened to 46.9% from 47.7% while operating income was flat at ~$16.5M.</li><li>Net income was up 28% to $15.2M while EPS was up 26% to $0.29.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392816\" data-linked=\"Neogen Q1 miss pressures shares, down 15%\" data-tweet=\"$NEOG - Neogen Q1 miss pressures shares, down 15% https://seekingalpha.com/news/3392816-neogen-q1-miss-pressures-shares-down-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3392816-neogen-q1-miss-pressures-shares-down-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392815\" data-ts=\"1537892480\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOLD\" target=\"_blank\">GOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392815-barrick-randgold-merger-sparks-gains-in-rival-miners-deals-seen\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barrick-Randgold merger sparks gains in rival miners as more deals seen</a></h4><ul>     <li>Barrick Gold's (ABX <font color='green'>+2.1%</font>) <a href=\"https://seekingalpha.com/news/3392296-barrick-gold-buy-randgold-resources-stock-deal\" target=\"_blank\">merger</a> with Randgold Resources (<a href='https://seekingalpha.com/symbol/GOLD' title='Barrick Gold Corporation'>GOLD</a> <font color='green'>+3.4%</font>) is sparking hopes for more deals in the heretofore unloved gold sector, <a href=\"https://www.ft.com/content/41dc3d40-c0d7-11e8-8d55-54197280d3f7\" target=\"_blank\">lifting shares of rival miners</a> including Gold Fields (<a href='https://seekingalpha.com/symbol/GFI' title='Gold Fields Limited'>GFI</a> <font color='green'>+1.8%</font>), Sibanye Stillwater (<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='green'>+2%</font>), AngloGold Ashanti (<a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color='green'>+0.6%</font>), IAMGOLD&nbsp;(<a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a> <font color='green'>+1.5%</font>) and KIrkland Lake Gold (<a href='https://seekingalpha.com/symbol/KL' title='Kirkland Lake Gold Ltd.'>KL</a> <font color='green'>+4.8%</font>).</li>     <li>The deal could &ldquo;could spur a pick-up in M&amp;A, which in our view could result in a turnaround in mining equity performance,&rdquo; RBC analysts say; mergers and acquisitions have become cheaper than expanding reserves of gold through exploration, says the Coast Capital hedge fund.</li>     <li>The combined gold  reserves still buried in mines <a href=\"http://www.miningweekly.com/article/barricks-randgold-acquisition-may-spur-more-gold-mining-deals-2018-09-25\" target=\"_blank\">shrank by nearly half</a> to 11.3M oz. last year from its 2012 peak, according to Bloomberg, highlighting the urgency for mining companies to add projects to boost their production outlook and revive fading investor interest in the sector.</li>     <li>Analysts say smaller miners also could benefit by buying non-core assets ABX wants to sell; the deal has even revived speculation that ABX could return to the negotiating table with Newmont Mining (<a href='https://seekingalpha.com/symbol/NEM' title='Newmont Mining Corporation &#40;Holding Company&#41;'>NEM</a> <font color='red'>-0.1%</font>) for a new tie-up after talks between the two collapsed in 2014.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a>, <a href='https://seekingalpha.com/symbol/NUGT' title='Direxion Daily Gold Miners Index Bull 3x Shares ETF'>NUGT</a>, <a href='https://seekingalpha.com/symbol/GDXJ' title='VanEck Vectors Junior Gold Miners ETF'>GDXJ</a>, <a href='https://seekingalpha.com/symbol/JNUG' title='Direxion Daily Junior Gold Miners Index Bull 3x Shares ETF'>JNUG</a>, <a href='https://seekingalpha.com/symbol/GGN' title='GAMCO Global Gold, Natural Resources & Income Trust'>GGN</a>, <a href='https://seekingalpha.com/symbol/DUST' title='Direxion Daily Gold Miners Index Bear 3x Shares ETF'>DUST</a>, <a href='https://seekingalpha.com/symbol/JDST' title='Direxion Daily Junior Gold Miners Index Bear 3x Shares ETF'>JDST</a>, <a href='https://seekingalpha.com/symbol/GOEX' title='Global X Gold Explorers ETF'>GOEX</a>, <a href='https://seekingalpha.com/symbol/SGDM' title='Sprott Gold Miners ETF'>SGDM</a>, <a href='https://seekingalpha.com/symbol/ASA' title='ASA Gold&Precious Metals'>ASA</a>, <a href='https://seekingalpha.com/symbol/RING' title='iShares MSCI Global Gold Miners ETF'>RING</a>, <a href='https://seekingalpha.com/symbol/SGDJ' title='Sprott Junior Gold Miners ETF'>SGDJ</a>, <a href='https://seekingalpha.com/symbol/TGLDX' title='Tocqueville Gold Fund No Load'>TGLDX</a>, <a href='https://seekingalpha.com/symbol/PSAU' title='Invesco Global Gold and Precious Metals Portfolio ETF'>PSAU</a>, <a href='https://seekingalpha.com/symbol/GOAU' title='U.S. Global GO GOLD and Precious Metal Miners ETF'>GOAU</a>, <a href='https://seekingalpha.com/symbol/GDXX' title='ProShares Ultra Gold Miners ETF'>GDXX</a>, <a href='https://seekingalpha.com/symbol/GDXS' title='ProShares UltraShort Gold Miners ETF'>GDXS</a>, <a href='https://seekingalpha.com/symbol/MELT' title='Direxion Daily Gold Miners Index Bear 1x Shares ETF'>MELT</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3392815\" data-linked=\"Barrick-Randgold merger sparks gains in rival miners as more deals seen\" data-tweet=\"$GOLD $GOLD $GFI - Barrick-Randgold merger sparks gains in rival miners as more deals seen https://seekingalpha.com/news/3392815-barrick-randgold-merger-sparks-gains-in-rival-miners-deals-seen?source=tweet\" data-url=\"https://seekingalpha.com/news/3392815-barrick-randgold-merger-sparks-gains-in-rival-miners-deals-seen\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392804\" data-ts=\"1537891472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/I\" target=\"_blank\">I</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392804-intelsatplus-15-ahead-of-ariane-5-rocket-launch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intelsat +15% ahead of Ariane 5 rocket launch</a></h4><ul><li>        Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a>) shares<font color='green'> pop 15.4%</font>&nbsp;as Europe&rsquo;s Ariane 5 rocket <a href=\"https://www.theverge.com/2018/9/25/17900344/ariane-5-european-space-agency-arianespace-100th-flight\" target=\"_blank\">prepares to launch</a> its 100th mission to space.</li><li>               The Ariane 5 is putting a pair of communication satellites into high orbit: Intelsat and SKY Perfect JSAT&rsquo;s Horizons 3e and the Azerspace-2/Intelsat 38. &nbsp;&nbsp;</li><li>               The Azercosmos/Intelsat probe will provide direct-to-home services in Europe, Asia, and sub-Saharan Africa.&nbsp;</li><li>               The Ariane 5 launch window opens today at 5:53 PM ET and extends until 6:38 PM.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3392804\" data-linked=\"Intelsat +15% ahead of Ariane 5 rocket launch\" data-tweet=\"$I - Intelsat +15% ahead of Ariane 5 rocket launch https://seekingalpha.com/news/3392804-intelsatplus-15-ahead-of-ariane-5-rocket-launch?source=tweet\" data-url=\"https://seekingalpha.com/news/3392804-intelsatplus-15-ahead-of-ariane-5-rocket-launch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392802\" data-ts=\"1537891255\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBEV\" target=\"_blank\">NBEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392802-consumer-top-gainers-losers-of-12-00-pm-09-25-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 PM (09/25/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/MPX' title='Marine Products Corporation'>MPX</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods'>ANFI</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392802\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 PM (09/25/2018)\" data-tweet=\"$NBEV $NBEV $MPX - Consumer - Top Gainers / Losers as of 12:00 PM (09/25/2018) https://seekingalpha.com/news/3392802-consumer-top-gainers-losers-of-12-00-pm-09-25-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392802-consumer-top-gainers-losers-of-12-00-pm-09-25-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392788\" data-ts=\"1537889888\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FMS\" target=\"_blank\">FMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392788-recent-analyst-action-in-europe-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Recent analyst action in Europe - healthcare</a></h4><ul><li>Fresenius Medical Care (<a href='https://seekingalpha.com/symbol/FMS' title='Fresenius Medical Care AG & Co. KGAA'>FMS</a> <font color='green'>+1.5%</font>)(<a href='https://seekingalpha.com/symbol/FMCQF' title='Fresenius Medical Care AG & Co KGaA'>OTCPK:FMCQF</a>)(<a href='https://seekingalpha.com/symbol/FSMEM' title='Fresenius Medical Care Holdings'>OTCPK:FSMEM</a>) assumed with Hold rating and &euro;82 price target at Jefferies.</li><li>Fresenius SE (<a href='https://seekingalpha.com/symbol/FSNUF' title='Fresenius SE & Co. KGaA'>OTCQX:FSNUF</a>) (<a href='https://seekingalpha.com/symbol/FSNUY' title='Fresenius SE & Co. KGaA ADR'>OTCQX:FSNUY</a>) assumed with Hold rating and &euro;59 price target at Jefferies.</li><li>Spire Healthcare Group &#40;SPI&#41;(<a href='https://seekingalpha.com/symbol/SRRHF' title='Spire Healthcare Group PLC'>OTC:SRRHF</a>) resumed with Hold rating at Liberum.</li><li>Genmab A/S (<a href='https://seekingalpha.com/symbol/GNMSF' title='Genmab A/S'>OTCPK:GNMSF</a>)(<a href='https://seekingalpha.com/symbol/GMXAY' title='Genmab A/S ADR'>OTCPK:GMXAY</a> <font color='green'>+3.4%</font>) upgraded to Buy with a DKK1,200 (13% upside) price target.</li><li>Takeda Pharmaceutical (<a href='https://seekingalpha.com/symbol/TKPHF' title='Takeda Pharmaceutical Co., Ltd.'>OTCPK:TKPHF</a>)(TKPYY) upgraded to Outperform with a &yen;5,600 (18% upside) price target at Daiwa.</li><li>Lysogene &#40;LYS&#41; downgraded to Reduce with a &euro;2.10 (15% upside) price target at Gilbert Dupont.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392788\" data-linked=\"Recent analyst action in Europe - healthcare\" data-tweet=\"$FMS $FMS $FMCQF - Recent analyst action in Europe - healthcare https://seekingalpha.com/news/3392788-recent-analyst-action-in-europe-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3392788-recent-analyst-action-in-europe-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392778\" data-ts=\"1537888312\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVS\" target=\"_blank\">NVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392778-novartis-to-cut-2000-jobs-in-restructuring-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novartis to cut 2,000 jobs in restructuring; shares up 1%</a></h4><ul><li>The WSJ <a href=\"https://www.wsj.com/articles/novartis-to-cut-2-000-jobs-amid-revamp-1537871477\" target=\"_blank\">reports </a>that Novartis (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='green'>+1%</font>) plans to axe more than 2,000 jobs as part of a global restructuring as it sharpens its focus on higher-value drugs. Most of the cuts will occur in its home market, about 1,000 in production and 700 in business services. The layoffs will occur through 2022.</li><li>The company also plans to cut 400 jobs at a plant in Britain, following previous announcements of cuts in the U.S., Japan and other countries.</li><li>CEO Vasant Narasimhan intends to focus the company on \"personalized and specified\" medicines. Consistent with this strategy, the company plans to divest its Alcon unit, valued at $20B, and back away from research in antibiotics and antivirals. Recently, it announced the sale of Sandoz unit's U.S. oral solids portfolio to India's Aurobindo Pharma for $900M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3388217-novartis-offloads-parts-sandoz-u-s\" target=\"_blank\">Novartis offloads parts of Sandoz U.S.</a> (Sept. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392778\" data-linked=\"Novartis to cut 2,000 jobs in restructuring; shares up 1%\" data-tweet=\"$NVS - Novartis to cut 2,000 jobs in restructuring; shares up 1% https://seekingalpha.com/news/3392778-novartis-to-cut-2000-jobs-in-restructuring-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3392778-novartis-to-cut-2000-jobs-in-restructuring-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392773\" data-ts=\"1537887717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGTC\" target=\"_blank\">AGTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392773-healthcare-top-5-gainers-losers-of-11-00-09-25-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 AM (09/25/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AGTC' title='Applied Genetic Technologies Corporation'>AGTC</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/OXFD' title='Oxford Immunotec Global PLC'>OXFD</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/OASM' title='Oasmia Pharmaceutical'>OASM</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/TYME' title='Tyme Technologies, Inc.'>TYME</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a> <font color='red'>-35%</font>. <a href='https://seekingalpha.com/symbol/DCTH' title='Delcath Systems, Inc.'>OTC:DCTH</a> <font color='red'>-29%</font>. <a href='https://seekingalpha.com/symbol/CKPT' title='CHECKPOINT THERAPEUTICS'>CKPT</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='red'>-19%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392773\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 AM (09/25/2018)\" data-tweet=\"$AGTC $AGTC $OXFD - Healthcare - Top 5 Gainers / Losers as of 11:00 AM (09/25/2018) https://seekingalpha.com/news/3392773-healthcare-top-5-gainers-losers-of-11-00-09-25-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392773-healthcare-top-5-gainers-losers-of-11-00-09-25-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392774\" data-ts=\"1537887679\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CY\" target=\"_blank\">CY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392774-cypress-semiminus-6-after-keybanc-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cypress Semi -6% after KeyBanc downgrade</a></h4><ul><li>        KeyBanc <a href=\"https://www.streetinsider.com/Analyst+Comments/KeyBanc+Downgrades+Cypress+Semi+%28CY%29+to+Sector+Weight/14638299.html\" target=\"_blank\">downgrades</a> Cypress Semiconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/CY' title='Cypress Semiconductor Corporation'>CY</a>) from Overweight to Sector Weight.</li><li>               Analyst Weston Twigg cites concerns on an automotive market slowdown, particularly in China, with auto accounting for about 30% of CY revenue.&nbsp;</li><li>               Twigg thinks NOR flash pricing has begun to ease and voices broader risk concerns about a cyclical slowdown.&nbsp;</li><li>               Cypress Semi shares are&nbsp;<font color='red'>down 6.1%</font>&nbsp;to $14.58.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392406-cypress-semi-minus-5-percent-morgan-stanley-lowers-target-margin-forecast\" target=\"_blank\">Cypress Semi -5% after Morgan Stanley lowers target, margin forecast</a> (Sept. 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392774\" data-linked=\"Cypress Semi -6% after KeyBanc downgrade\" data-tweet=\"$CY - Cypress Semi -6% after KeyBanc downgrade https://seekingalpha.com/news/3392774-cypress-semiminus-6-after-keybanc-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3392774-cypress-semiminus-6-after-keybanc-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392763\" data-ts=\"1537886802\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DHXM\" target=\"_blank\">DHXM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392763-dhx-media-jumps-21-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DHX Media jumps 21% post Q4 results</a></h4><ul><li>DHX Media (<a href='https://seekingalpha.com/symbol/DHXM' title='DHX Media Ltd Variable Voting'>DHXM</a> <font color='green'>+21.5%</font>) reported Q4 revenue growth of 11.2% Y/Y to C$97.4M, driven by the acquisition of Peanuts and Strawberry Shortcake, and by continued growth in WildBrain.</li><li>Q4 Gross margin&nbsp;<font color='red'>decline by 246 bps</font>&nbsp;to 43.3%, due to the new mix of the Company's business with Peanuts, as well as continued growth in third-party revenues from WildBrain.</li><li>Adj. EBITDA decreased by 32.5% Y/Y to C$16M and margin&nbsp;<font color='red'>declined by 1,063 bps&nbsp;</font>to 16.4%.</li><li>Q4 2018 generated positive operating cash flow of C$8.3M, compared to C$6.9M a year ago.</li><li>Leverage ratio was at 6.1x as of June 30, 2018.</li><li>Company closed the sale of a minority stake in Peanuts to Sony Music Entertainment (Japan) Inc.,the net proceeds of C$210M&nbsp;were used to repay a portion of the term loan.</li><li>\"Reducing leverage is one of our key priorities. The Sony transaction was a significant step in that direction and ensures we have the financial flexibility to maintain investment in growth. Our operations are providing improving free cash flow. In combination with cash savings from the quarterly dividend suspension, that provides additional funds for debt repayment\", commented&nbsp;Doug Lamb, CFO, DHX Media.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392613-dhx-media-reports-q4-results\" target=\"_blank\">DHX Media reports Q4 results</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392763\" data-linked=\"DHX Media jumps 21% post Q4 results\" data-tweet=\"$DHXM - DHX Media jumps 21% post Q4 results https://seekingalpha.com/news/3392763-dhx-media-jumps-21-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3392763-dhx-media-jumps-21-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392767\" data-ts=\"1537886671\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DHXM\" target=\"_blank\">DHXM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392767-dhx-media-fq4-top-line-up-11-shares-ahead-22\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DHX Media FQ4 top line up 11%; shares ahead 22%</a></h4><ul><li>DHX Media (<a href='https://seekingalpha.com/symbol/DHXM' title='DHX Media Ltd Variable Voting'>DHXM</a> <font color='green'>+21.5%</font>) <a href=\"https://seekingalpha.com/pr/17279275-dhx-media-reports-results-fiscal-2018\" target=\"_blank\">fiscal Q4 results</a> ($M): Revenue: 97.4 (+11.2%); net loss: (6.8) (+62.8%).</li><li>Cost cutting initiatives expected to trim ~$11M in annual expenses going forward.</li><li>Fiscal 2019 priorities include brand-building on WildBrain, developing premium kids content to drive brands and strengthening cash flow and balance sheet.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392767\" data-linked=\"DHX Media FQ4 top line up 11%; shares ahead 22%\" data-tweet=\"$DHXM - DHX Media FQ4 top line up 11%; shares ahead 22% https://seekingalpha.com/news/3392767-dhx-media-fq4-top-line-up-11-shares-ahead-22?source=tweet\" data-url=\"https://seekingalpha.com/news/3392767-dhx-media-fq4-top-line-up-11-shares-ahead-22\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392766\" data-ts=\"1537886595\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DNN\" target=\"_blank\">DNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392766-denison-chooses-isr-mining-method-for-wheeler-river-project\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Denison chooses ISR mining method for Wheeler River project</a></h4><ul><li>Denison Mines (<a href='https://seekingalpha.com/symbol/DNN' title='Denison Mines Corp'>DNN</a> <font color='green'>+2.8%</font>) says it has <a href=\"https://seekingalpha.com/pr/17279278-denison-reports-results-wheeler-river-pfs-including-plus-275-percent-increase-pre-tax-npv\" target=\"_blank\">selected the low-cost in-situ recovery mining  method</a> for the development of the high-grade Phoenix deposit at its flagship Wheeler River uranium project in Saskatchewan, marking the <a href=\"http://www.miningweekly.com/article/denison-selects-low-cost-isr-method-for-wheeler-river-project-2018-09-25\" target=\"_blank\">first deposit identified for ISR  mining</a> in Canada&rsquo;s Athabasca basin.</li><li>ISR is considered the world's lowest-cost uranium mining method, and  DNN says using it for the Phoenix deposit yields an estimated operating cost of  C$4.33/lb. (US$3.33/lb.) of uranium oxide.</li><li>Combined with the Gryphon deposit, which is seen as complementary to Phoenix and designed as an underground mining operation, DNN estimates the Wheeler River project to have mine production of 109.4M lbs. of uranium oxide over a 14-year mine life, with a base case pre-tax net present value of&nbsp;$1.31B, an internal rate of return of 38.7%, and initial  pre-production capex of&nbsp;$322M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392766\" data-linked=\"Denison chooses ISR mining method for Wheeler River project\" data-tweet=\"$DNN - Denison chooses ISR mining method for Wheeler River project https://seekingalpha.com/news/3392766-denison-chooses-isr-mining-method-for-wheeler-river-project?source=tweet\" data-url=\"https://seekingalpha.com/news/3392766-denison-chooses-isr-mining-method-for-wheeler-river-project\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392762\" data-ts=\"1537885758\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFN\" target=\"_blank\">INFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392762-infineraplus-3_5-morgan-stanley-reinstates-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Infinera +3.5% as Morgan Stanley reinstates Overweight</a></h4><ul>   <li>Infinera (NASDAQ:<a href='https://seekingalpha.com/symbol/INFN' title='Infinera Corporation'>INFN</a>) is <font color='green'>up 3.5%</font> after a reinstatement at Morgan Stanley at Overweight.</li>    <li>The firm has set its price target to $9.50, implying 31% upside.</li>    <li>Shares have <font color='red'>dropped 25%</font> over the past quarter, and are <font color='red'>down 36.6%</font> over the past six months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392762\" data-linked=\"Infinera +3.5% as Morgan Stanley reinstates Overweight\" data-tweet=\"$INFN - Infinera +3.5% as Morgan Stanley reinstates Overweight https://seekingalpha.com/news/3392762-infineraplus-3_5-morgan-stanley-reinstates-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3392762-infineraplus-3_5-morgan-stanley-reinstates-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392761\" data-ts=\"1537885700\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INTC\" target=\"_blank\">INTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392761-raymond-james-downgrades-intel-on-10nm-delay\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raymond James downgrades Intel on 10nm delay</a></h4><ul><li>        More color on the <a href=\"https://www.cnbc.com/2018/09/25/raymond-james-says-sell-intel-shares-due-to-its-chip-manufacturing-problems.html\" target=\"_blank\">Raymond James downgrade</a> of Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) this morning from Market Perform to Underperform with no assigned price target. &nbsp;</li><li>        Analyst Chris Caso: &ldquo;Intel&rsquo;s biggest strategic problem is their delay on 10nm production &ndash; we don&rsquo;t expect a 10nm server chip from Intel for two years. 10nm delays create a window for competitors, and the window may never again close.&rdquo;</li><li>        In July, Intel said its 10nm chips would release for holiday 2019. AMD&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) 7nm server chips, manufactured by TSMC (NYSE:<a href='https://seekingalpha.com/symbol/TSM' title='Taiwan Semiconductor Manufacturing Company Ltd.'>TSM</a>), will have a volume launch sometime next year. &nbsp;</li><li>        Caso says that &ldquo;Intel is standing still&rdquo; but &ldquo;TSMC isn&rsquo;t&rdquo; and that the delay will allow TSMC to become &ldquo;firmly in the lead.&rdquo;</li><li>               Intel shares are&nbsp;<font color='red'>down 1.8%</font>&nbsp;to $46.09. AMD is&nbsp;<font color='green'>up 1%</font>&nbsp;to $32.94 and TSMC is&nbsp;<font color='red'>down 0.9%</font>&nbsp;to $44.50.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392692-raymond-james-tech-downgrades-include-intel-analog-devices\" target=\"_blank\">Raymond James tech downgrades include Intel, Analog Devices</a> (Sept. 25)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392723-qualcomm-charges-apple-stealing-secrets-giving-intel\" target=\"_blank\">Qualcomm charges Apple with stealing secrets, giving to Intel</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392761\" data-linked=\"Raymond James downgrades Intel on 10nm delay\" data-tweet=\"$INTC $INTC $AMD - Raymond James downgrades Intel on 10nm delay https://seekingalpha.com/news/3392761-raymond-james-downgrades-intel-on-10nm-delay?source=tweet\" data-url=\"https://seekingalpha.com/news/3392761-raymond-james-downgrades-intel-on-10nm-delay\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>76&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392745\" data-ts=\"1537884194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SONC\" target=\"_blank\">SONC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392745-sonic-leads-restaurant-sector-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sonic leads the restaurant sector higher</a></h4><ul> <li>Trading on Sonic (<a href='https://seekingalpha.com/symbol/SONC' title='Sonic Corp.'>SONC</a> <font color='green'>+18.8%</font>) has started up again after a delay following the company's buyout announcement during the premarket session.</li> <li>Sonic is swapping hands just slightly above the takeover price of $43.50 at the moment, but ranged as high as $44.87 earlier.</li> <li>Restaurant stocks are pretty active in early trading as investors gauge the sector following the private interest in Sonic.</li> <li>Restaurant runners: Jack In the Box (NASDAQ:<a href='https://seekingalpha.com/symbol/JACK' title='Jack In The Box Inc.'>JACK</a>)&nbsp;<font color='green'>+2.8%</font>, Wingstop (NASDAQ:<a href='https://seekingalpha.com/symbol/WING' title='Wingstop, Inc.'>WING</a>)<font color='green'> +2.5%</font>, Red Robin Gourmet Burgers (NASDAQ:<a href='https://seekingalpha.com/symbol/RRGB' title='Red Robin Gourmet Burgers, Inc.'>RRGB</a>)&nbsp;<font color='green'>+1.7%</font>, BJ's Restaurants (NASDAQ:<a href='https://seekingalpha.com/symbol/BJRI' title='BJ&#39;s Restaurants, Inc.'>BJRI</a>)&nbsp;<font color='green'>+1.7%</font>, Wendy's (NYSE:<a href='https://seekingalpha.com/symbol/WEN' title='The Wendy&#39;s Company'>WEN</a>)&nbsp;<font color='green'>+1.6%</font>, Habit Restaurants (NASDAQ:<a href='https://seekingalpha.com/symbol/HABT' title='The Habit Restaurants'>HABT</a>)&nbsp;<font color='green'>+1.5%</font>, J. Alexander's (NASDAQ:<a href='https://seekingalpha.com/symbol/JAX' title='J. Alexander&#39;s Holdings, Inc.'>JAX</a>)&nbsp;<font color='green'>+1.3%</font>, The ONE Group (NASDAQ:<a href='https://seekingalpha.com/symbol/STKS' title='The ONE Group Hospitality, Inc.'>STKS</a>)&nbsp;<font color='green'>+1.3%</font>, and Carrols Restaurants (NASDAQ:<a href='https://seekingalpha.com/symbol/TAST' title='Carrols Restaurant Group, Inc.'>TAST</a>)&nbsp;<font color='green'>+1.1%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392724-inspire-brands-acquire-sonic\" target=\"_blank\">Inspire Brands to acquire Sonic</a> (Sept. 25)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392731-sonic-goes-private-2_3b-deal\" target=\"_blank\">Sonic goes private in $2.3B deal</a> (Sept. 25)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3392745\" data-linked=\"Sonic leads the restaurant sector higher\" data-tweet=\"$SONC $SONC $JACK - Sonic leads the restaurant sector higher https://seekingalpha.com/news/3392745-sonic-leads-restaurant-sector-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3392745-sonic-leads-restaurant-sector-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392743\" data-ts=\"1537883854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392743-astrazenecas-imfinzi-improved-survival-in-late-stage-lung-cancer-study-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca&#39;s Imfinzi improved survival in late-stage lung cancer study; shares up 2%</a></h4><ul><li><a href=\"https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-is-the-first-immunotherapy-to-demonstrate-significant-overall-survival-benefit-in-unresectable-stage-iii-lung-cancer25092018.html\" target=\"_blank\">Results </a>from a Phase 3 clinical trial, PACIFIC, evaluating AstraZeneca's (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='green'>+1.8%</font>) Imfinzi (durvalumab) in patients with locally advanced unresectable non-small cell lung cancer &#40;NSCLC&#41; showed a statistically significant improvement in survival compared to standard-of-care treatment regardless of PD-L1 expression. The data were presented at the World Conference on Lung Cancer in Toronto.</li><li>At data cutoff, the mortality rate in the Imfinzi group was 38.4% compared to 48.9% for control with a hazard ratio of 0.68 (32% less risk of death in the Imfinzi cohort).</li><li>The five-survival rate in these patients has historically been ~15% after chemoradiation treatment.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392454-astrazenecas-imfinzi-okd-europe-advanced-lung-cancer\" target=\"_blank\">AstraZeneca's Imfinzi OK'd in Europe for advanced lung cancer</a> (Sept. 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392743\" data-linked=\"AstraZeneca&#39;s Imfinzi improved survival in late-stage lung cancer study; shares up 2%\" data-tweet=\"$AZN - AstraZeneca&#39;s Imfinzi improved survival in late-stage lung cancer study; shares up 2% https://seekingalpha.com/news/3392743-astrazenecas-imfinzi-improved-survival-in-late-stage-lung-cancer-study-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3392743-astrazenecas-imfinzi-improved-survival-in-late-stage-lung-cancer-study-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392739\" data-ts=\"1537883176\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HP\" target=\"_blank\">HP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392739-helmerich-payneplus-3-after-b-riley-fbr-upgrades-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Helmerich &amp; Payne +3% after B. Riley FBR upgrades to Buy</a></h4><ul>     <li>Helmerich &amp;&nbsp;Payne (NYSE:<a href='https://seekingalpha.com/symbol/HP' title='Helmerich & Payne Inc.'>HP</a>) jumps at the open after B. Riley FBR <a href=\"https://www.streetinsider.com/Analyst+Comments/B.RileyFBR+Upgrades+Helmerich+%26+Payne+%28HP%29+to+Buy/14638327.html\" target=\"_blank\">upgrades shares to Buy</a> from Neutral and raises its price target to $83 from $68, citing valuation as well as HP's technology and super spec strategy.</li>     <li>The firm foresees HP reaping the rewards from a proven growth strategy for a U.S. super-spec land  drilling market with bullish cyclical and secular dynamics, and potential earnings upside that could be generated by HP's AutoSlide automated directional drilling service, which is set for commercial launch in H1 2019.</li>     <li>In a full catch-up for CY Q2 results and  guidance as well as recent land drilling market trends, B. Riley raises its outlook for EBITDA and EPS for FY 2018 and 2019 from $608M/$0.02 and $795M/$1.28 to $625M/$0.13 and $901M/$1.95.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392739\" data-linked=\"Helmerich &amp; Payne +3% after B. Riley FBR upgrades to Buy\" data-tweet=\"$HP - Helmerich &amp; Payne +3% after B. Riley FBR upgrades to Buy https://seekingalpha.com/news/3392739-helmerich-payneplus-3-after-b-riley-fbr-upgrades-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3392739-helmerich-payneplus-3-after-b-riley-fbr-upgrades-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392738\" data-ts=\"1537882945\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRUB\" target=\"_blank\">GRUB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392738-grubhub-to-acquire-tapingo-for-150m-sharesplus-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GrubHub to acquire Tapingo for $150M; shares +3%</a></h4><ul>   <li>GrubHub (<a href=\"http://seekingalpha.com/symbol/GRUB\" target=\"_blank\">GRUB</a> <font color='green'>+3%</font>) has set a deal to <a href=\"https://seekingalpha.com/pr/17280073-grubhub-announces-acquisition-tapingo\" target=\"_blank\">acquire Tapingo</a>, a specialist in campus food ordering, for about $150M.</li>    <li>Tapingo has more than 150 college campus partners and says it enables tens of thousands of transactions for more than half a million active diners at on-campus cafes, restaurants and cashierless stores.</li>    <li>It counts among its partners Aramark and Sodexo, as well as Taco Bell, Chipotle, Chick-fil-A, Panda Express and Jamba Juice.</li>    <li>The company has technical teams in the U.S. and Israel.</li>    <li>The deal's expected to close in Q4.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392738\" data-linked=\"GrubHub to acquire Tapingo for $150M; shares +3%\" data-tweet=\"$GRUB - GrubHub to acquire Tapingo for $150M; shares +3% https://seekingalpha.com/news/3392738-grubhub-to-acquire-tapingo-for-150m-sharesplus-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3392738-grubhub-to-acquire-tapingo-for-150m-sharesplus-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392732\" data-ts=\"1537882773\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DAC\" target=\"_blank\">DAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392732-danaos-positive-post-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Danaos positive post Q2 results</a></h4><ul><li>Danaos (<a href='https://seekingalpha.com/symbol/DAC' title='Danaos Corporation'>DAC</a>)&nbsp;<a href=\"https://seekingalpha.com/pr/17279113-danaos-corporation-reports-second-quarter-half-year-results-period-ended-june-30-2018\" target=\"_blank\">reported Q2</a> revenue of $113.5M (-0.4% Y/Y).</li><li>Q2 overall operating margin&nbsp;<font color='green'>improved by 138 bps</font>&nbsp;to 42.9% and Adj. EBITDA margin&nbsp;<font color='green'>improved by 40 bps</font>&nbsp;to 68.9%.</li><li>Q2 expenses: Vessel operating $26.7M (-1.8% Y/Y), G&amp;A $5.8M (+9.4% Y/Y) and Voyage $3.2M (flat Y/Y).</li><li>Company&rsquo;s fleet utilization for the quarter was 96.4%, with an average of 55 containerships and an average gross daily charter rate of $23,628.</li><li>Total contracted revenues were $1.6B as of June 30, 2018, with chatters extending to 2028 and average duration of 5.3 years.</li><li>The refinancing of ~$2.2B of debt maturing on December 31, 2018, reduced debt by ~$551M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392576-danaos-beats-0_04-beats-revenue\" target=\"_blank\">Danaos beats by $0.04, beats on revenue</a> (Sept. 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392732\" data-linked=\"Danaos positive post Q2 results\" data-tweet=\"$DAC - Danaos positive post Q2 results https://seekingalpha.com/news/3392732-danaos-positive-post-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3392732-danaos-positive-post-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392735\" data-ts=\"1537882575\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NIHD\" target=\"_blank\">NIHD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392735-nii-holdings-jumps-cowen-sees-143-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NII Holdings jumps as Cowen sees 143% upside</a></h4><ul>   <li>NII Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a>) has opened <font color='green'>up 12%</font> after Cowen says it's worth at least $14/share, based on a valuation of the company's Nextel Brasil at more than $2.5B.</li>    <li>Shares closed previously on Nasdaq at $4.97.</li>    <li>Chatter has been growing about a possible takeout of Nextel Brasil by TIM Participa&ccedil;&otilde;es (<a href='https://seekingalpha.com/symbol/TSU' title='TIM Participações S.A.'>TSU</a> <font color='red'>-1.1%</font>), the Brazilian unit of Telecom Italia (NYSE:<a href='https://seekingalpha.com/symbol/TI' title='Telecom Italia S.P.A.'>TI</a>), a buyer that Cowen has highlighted.</li>    <li><a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> is <font color='green'>up 137.6%</font> over the past six months and <font color='green'>up 908.6%</font> over the past 12.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392735\" data-linked=\"NII Holdings jumps as Cowen sees 143% upside\" data-tweet=\"$NIHD $NIHD $TSU - NII Holdings jumps as Cowen sees 143% upside https://seekingalpha.com/news/3392735-nii-holdings-jumps-cowen-sees-143-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3392735-nii-holdings-jumps-cowen-sees-143-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392733\" data-ts=\"1537882462\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASCMA\" target=\"_blank\">ASCMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392733-ascent-capitalminus-5_7-after-support-pact-monitronics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ascent Capital -5.7% after support pact with Monitronics</a></h4><ul><li>Ascent Capital Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ASCMA' title='Ascent Capital Group, Inc.'>ASCMA</a>)&nbsp;<font color='red'>slumps 5.7%</font>&nbsp;in early trading after announcing a <a href=\"https://seekingalpha.com/pr/17279574-ascent-capital-group-monitronics-international-announce-execution-support-agreement-certain\" target=\"_blank\">transaction support agreement </a>with holders of about $386M of Monitronics International's 9.125% senior notes (Old MONI notes) due 2020, about 66% of Old MONI notes outstanding.</li><li>As a result of the support pact, Ascent and its Monitronics subsidiary have terminated an exchange offer that was announced on Aug. 30, 2018 and propose a new exchange offer.</li><li>Under the new proposal, MONI would offer to exchange Old MONI notes for new second lien notes and seek to change the Old MONI note indenture to eliminate or waive substantially all restrictive covenants and events of default.</li><li>MONI would seek to amend its senior secured credit facility to permit MONI to issue second lien notes and third lien notes and</li><li>MONI would pay down $100M principal amount of term loans outstanding with cash funded by Ascent and revolving loan commitments under the credit line would be permanently cut by 10%.</li><li>Also, An offer would be made to exchange Ascent convertible notes for new third lien notes issued by MONI.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387116-ascent-capital-starts-tender-offer-4_00-percent-notes-exchange-offer-moni-notes\" target=\"_blank\">Ascent Capital starts tender offer for 4.00% notes, exchange offer for MONI notes</a> (Aug. 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392733\" data-linked=\"Ascent Capital -5.7% after support pact with Monitronics\" data-tweet=\"$ASCMA $SCTY - Ascent Capital -5.7% after support pact with Monitronics https://seekingalpha.com/news/3392733-ascent-capitalminus-5_7-after-support-pact-monitronics?source=tweet\" data-url=\"https://seekingalpha.com/news/3392733-ascent-capitalminus-5_7-after-support-pact-monitronics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392728\" data-ts=\"1537882111\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPNT\" target=\"_blank\">OPNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392728-opiant-prices-stock-offering-17-shares-down-19-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Opiant prices stock offering at $17; shares down 19% premarket</a></h4><ul><li>Opiant Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a>) slumps&nbsp;<font color='red'>19%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/17280296-opiant-pharmaceuticals-announces-pricing-public-offering-common-stock\" target=\"_blank\">public offering</a> of ~706K common shares at $17 per share. Yesterday's close was $21.32.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392728\" data-linked=\"Opiant prices stock offering at $17; shares down 19% premarket\" data-tweet=\"$OPNT - Opiant prices stock offering at $17; shares down 19% premarket https://seekingalpha.com/news/3392728-opiant-prices-stock-offering-17-shares-down-19-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3392728-opiant-prices-stock-offering-17-shares-down-19-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392727\" data-ts=\"1537882004\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGTX\" target=\"_blank\">TGTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392727-premarket-losers-of-9-05-09-25-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (09/25/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a>&nbsp;<font color='red'>-28%&nbsp;</font><a href=\"https://seekingalpha.com/news/3392663-tg-therapeutics-backs-away-response-rate-endpoint-late-stage-study-u2-cll-accelerated\" target=\"_blank\">backs away</a> from response rate endpoint in late-stage study of U2 in CLL, accelerated approval off the table.</li><li><a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a>&nbsp;<font color='red'>-18%</font>&nbsp;on stock <a href=\"https://seekingalpha.com/news/3392556-opiant-launches-stock-offering\" target=\"_blank\">offering</a>.</li><li><a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a>&nbsp;<font color='red'>-9%</font>.</li><li><a href='https://seekingalpha.com/symbol/SNDX' title='Syndax Pharmaceuticals, Inc.'>SNDX</a>&nbsp;<font color='red'>-10%</font>&nbsp;on on updated mid-stage data on entinostat/pembrolizumab combo in lung cancer.</li><li><a href='https://seekingalpha.com/symbol/LGCY' title='Legacy Reserves Inc'>LGCY</a>&nbsp;<font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a>&nbsp;<font color='red'>-7%</font>.</li><li><a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a>&nbsp;<font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392727\" data-linked=\"Premarket Losers as of 9:05 am (09/25/2018)\" data-tweet=\"$TGTX $TGTX $OPNT - Premarket Losers as of 9:05 am (09/25/2018) https://seekingalpha.com/news/3392727-premarket-losers-of-9-05-09-25-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392727-premarket-losers-of-9-05-09-25-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392719\" data-ts=\"1537881566\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CWEN\" target=\"_blank\">CWEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392719-clearway-energy-launches-3_9m-share-public-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clearway Energy launches 3.9M-share public offering</a></h4><ul>     <li>Clearway Energy (<a href='https://seekingalpha.com/symbol/CWEN' title='Clearway Energy, Inc.  Class C'>CWEN</a>, <a href='https://seekingalpha.com/symbol/CWEN.A' title='NRG Yield Inc'>CWEN.A</a>) <font color='red'>-2.8%</font> pre-market after commencing a <a href=\"https://seekingalpha.com/pr/17279091-clearway-energy-inc-announces-proposed-offering-class-c-common-stock\" target=\"_blank\">public offering</a> of more than 3.9M class C common shares to help fund its acquisition of the 527 MW Carlsbad natural gas fired project in California.</li>     <li>Earlier this month, CWEN priced a $600M offering of  senior notes due 2025, with part of the proceeds directed to help fund the Carlsbad acquisition.</li>     <li>Global Infrastructure Partners recently completed its acquisition of NRG Energy's interest in NRG Yield, which then changed its name to Clearway Energy.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392719\" data-linked=\"Clearway Energy launches 3.9M-share public offering\" data-tweet=\"$CWEN $CWEN $CWEN.A - Clearway Energy launches 3.9M-share public offering https://seekingalpha.com/news/3392719-clearway-energy-launches-3_9m-share-public-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3392719-clearway-energy-launches-3_9m-share-public-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392718\" data-ts=\"1537881556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JONE\" target=\"_blank\">JONE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392718-premarket-gainers-of-9-05-09-25-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (09/25/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='green'>+47%</font>.</li><li><a href='https://seekingalpha.com/symbol/APDN' title='Applied DNA Sciences, Inc.'>APDN</a> <font color='green'>+21%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17279364-applied-dna-expands-cannabis-tagging-portfolio-address-large-growers\" target=\"_blank\">expanding</a> cannabis tagging portfolio to address large growers.</li><li><a href='https://seekingalpha.com/symbol/CDTI' title='Clean Diesel Technologies, Inc.'>OTC:CDTI</a> <font color='green'>+18%</font>.</li><li><a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color='green'>+18%</font>&nbsp;on medical cannabis <a href=\"https://seekingalpha.com/news/3392662-tilray-20_6-percent-medical-cannabis-supply-australia\" target=\"_blank\">supply</a> to Australia.</li><li><a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a> <font color='green'>+18%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3392542-ascena-retail-group-beats-0_05-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> <font color='green'>+14%</font>.</li><li><a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+13%</font>.</li><li><a href='https://seekingalpha.com/symbol/QTNT' title='Quotient Limited'>QTNT</a> <font color='green'>+8%</font>&nbsp;on the <a href=\"https://seekingalpha.com/pr/17279732-quotient-limited-reports-submission-initial-ih-ce-mark-filing-successful-completion-key\" target=\"_blank\">submission</a> of its completed dossier for the CE mark of its initial MosaiQ IH product as planned; and (ii) the successful completion of the key regulatory audits required for the &nbsp;consolidation of its liquid reagent manufacturing into the new Allan Robb Campus facility.</li><li><a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17280025-tandem-diabetes-care-increases-2018-sales-guidance-provides-estimated-third-quarter-sales\" target=\"_blank\">increased</a> 2018 sales guidance and estimated 3Q18 results.</li><li><a href='https://seekingalpha.com/symbol/RETA' title='Reata Pharmaceuticals'>RETA</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3392671-reatas-bardoxolone-successful-mid-stage-study-rare-types-kidney-disease\" target=\"_blank\">successful</a> in mid-stage study in rare types of kidney disease.</li><li><a href='https://seekingalpha.com/symbol/GERN' title='Geron Corporation'>GERN</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a> <font color='green'>+6%</font>&nbsp;as FDA has granted Orphan Drug Designation to CLR 131 for the treatment of pediatric osteosarcoma.</li><li><a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corp.'>ADMP</a> <font color='green'>+5%</font>.</li><li><a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a> <font color='green'>+5%</font>.</li><li><a href='https://seekingalpha.com/symbol/GOLD' title='Barrick Gold Corporation'>GOLD</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392718\" data-linked=\"Premarket Gainers as of 9:05 am (09/25/2018)\" data-tweet=\"$JONE $JONE $APDN - Premarket Gainers as of 9:05 am (09/25/2018) https://seekingalpha.com/news/3392718-premarket-gainers-of-9-05-09-25-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392718-premarket-gainers-of-9-05-09-25-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392717\" data-ts=\"1537881444\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALDX\" target=\"_blank\">ALDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392717-aldeyras-ganetespib-shows-positive-effect-in-mesothelioma-study-shares-ahead-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aldeyra&#39;s ganetespib shows positive effect in mesothelioma study; shares ahead 5% premarket</a></h4><ul><li>Thinly traded micro cap Aldeyra Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a>) is up&nbsp;<font color='green'>5%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17279766-aldeyra-therapeutics-announces-positive-mesothelioma-investigator-sponsored-clinical-trial\" target=\"_blank\">announcement </a>of positive data from a Phase 1/2 clinical trial, MESO-2, evaluating ADX-1612 (ganetespib), combined with pemetrexed and platinum-based chemo, in patients with pleural malignant mesothelioma. The results are being presented today at the World Conference on Lung Cancer in Toronto.</li><li>The overall response rate &#40;ORR&#41; was 61%, significantly higher that the historical ORR rates of 20 - 40% for standard-of-care treatment. The response rate was 76% in patients with epithelial histology (cancer is located in the epithelial cells, the most common type of mesothelioma).</li><li>The disease control rate (responders + those with stable cancer) was 96% (n=22/23). One patient with non-epithelial histology progressed.</li><li>Ganetespib inhibits heat shock protein 90 (Hsp90), a molecular chaperone that controls the folding and activation of certain proteins involved in DNA repair and cell division. <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/14624223\" target=\"_blank\">Hsp90 </a>promotes cancer cell proliferation and survival so inhibiting its signaling inhibits the cancer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392717\" data-linked=\"Aldeyra&#39;s ganetespib shows positive effect in mesothelioma study; shares ahead 5% premarket\" data-tweet=\"$ALDX - Aldeyra&#39;s ganetespib shows positive effect in mesothelioma study; shares ahead 5% premarket https://seekingalpha.com/news/3392717-aldeyras-ganetespib-shows-positive-effect-in-mesothelioma-study-shares-ahead-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3392717-aldeyras-ganetespib-shows-positive-effect-in-mesothelioma-study-shares-ahead-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392716\" data-ts=\"1537880900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOOP\" target=\"_blank\">LOOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392716-loop-industries-shuts-down-planned-125k-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Loop Industries shuts down planned 125K-share offering</a></h4><ul>     <li>Loop Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/LOOP' title='Loop Industries, Inc.'>LOOP</a>) <font color='green'>+4.7%</font> pre-market after <a href=\"https://www.sec.gov/Archives/edgar/data/1504678/000147793218004611/loop_8k.htm\" target=\"_blank\">terminating</a> its previously announced offering of 125K common shares at $8/share.</li>     <li>Loop says it continues to pursue various financing alternatives to fund its ongoing operations.</li><li>Yesterday, Loop announced a <a href=\"https://seekingalpha.com/pr/17277914-indorama-ventures-loop-industries-jv-introduce-new-era-pet-polyester-recycling\" target=\"_blank\">joint venture</a> with Thailand's Indorama Ventures to manufacture and commercialize sustainable polyester  resin to meet global demand from beverage and consumer  packaged goods companies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392716\" data-linked=\"Loop Industries shuts down planned 125K-share offering\" data-tweet=\"$LOOP - Loop Industries shuts down planned 125K-share offering https://seekingalpha.com/news/3392716-loop-industries-shuts-down-planned-125k-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3392716-loop-industries-shuts-down-planned-125k-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392715\" data-ts=\"1537880559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLX\" target=\"_blank\">CLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392715-clorox-higher-after-argus-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clorox higher after Argus upgrade</a></h4><ul> <li>Shares of Clorox (NYSE:<a href='https://seekingalpha.com/symbol/CLX' title='The Clorox Company'>CLX</a>) track higher in premarket trading after Argus moves to a Buy rating from Hold.</li> <li>\"We like Clorox&rsquo;s low-cost operations, strong market share in mid-price product categories, and efforts to boost revenue through innovation,\" reads the analyst note.</li> <li>The firm also points to Clorox's strong dividend (2.36% yield, 57.6% payout ratio).</li><li>Argus hikes its price target on Clorox to $175.</li><li>CLX <font color='green'>+1.48%</font> premarket to $152.17</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3392715\" data-linked=\"Clorox higher after Argus upgrade\" data-tweet=\"$CLX - Clorox higher after Argus upgrade https://seekingalpha.com/news/3392715-clorox-higher-after-argus-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3392715-clorox-higher-after-argus-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392709\" data-ts=\"1537880200\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VBIV\" target=\"_blank\">VBIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392709-vbi-vaccines-study-of-vbiminus-1901-in-gbm-to-continue-planned-shares-ahead-11-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VBI Vaccines&#39; study of VBI-1901 in GBM to continue as planned; shares ahead 11% premarket</a></h4><ul><li>Thinly traded micro cap VBI Vaccines (NASDAQ:<a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines'>VBIV</a>) is up&nbsp;<font color='green'>11%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17279671-vbi-vaccines-announces-second-positive-dsmb-review-phase-1-2a-study-vbiminus-1901-recurrent\" target=\"_blank\">announcement </a>the independent Data and Safety Monitoring Board has completed its second safety review of its ongoing Phase 1/2a clinical trial evaluating VBI-1901 in patients with recurrent glioblastoma &#40;GBM&#41;. It recommended the continuation of the study without modification.</li><li>VBI-1901, administered via intradermal injection, is an immunotherapy targeting cytomegalovirus &#40;CMV&#41; antigens gB and pp65. CMV infection is believed to be prevalent in a range of solid tumors so an anti-CMV dendritic cell vaccination regimen may extend overall survival in GBM patients.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323238-dosing-underway-early-stage-study-vbi-vaccines-vbiminus-1901-gbm\" target=\"_blank\">Dosing underway in early-stage study of VBI Vaccines' VBI-1901 in GBM</a> (Jan. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392709\" data-linked=\"VBI Vaccines&#39; study of VBI-1901 in GBM to continue as planned; shares ahead 11% premarket\" data-tweet=\"$VBIV - VBI Vaccines&#39; study of VBI-1901 in GBM to continue as planned; shares ahead 11% premarket https://seekingalpha.com/news/3392709-vbi-vaccines-study-of-vbiminus-1901-in-gbm-to-continue-planned-shares-ahead-11-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3392709-vbi-vaccines-study-of-vbiminus-1901-in-gbm-to-continue-planned-shares-ahead-11-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392706\" data-ts=\"1537879566\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDXG\" target=\"_blank\">MDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392706-mimedx-up-6-premarket-on-positive-data-on-dhuc-in-diabetic-foot-ulcers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MiMedx up 6% premarket on positive data on dHUC in diabetic foot ulcers</a></h4><ul><li>MiMedx Group (<a href='https://seekingalpha.com/symbol/MDXG' title='MiMedx Group Inc.'>OTC:MDXG</a>) is up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume on the heels of the <a href=\"https://seekingalpha.com/pr/17279895-mimedx-publishes-positive-results-clinical-study-human-umbilical-cord-diabetic-foot-ulcers\" target=\"_blank\">publication </a>of a study evaluating its dehydrated human umbilical cord (dHUC) for the treatment of chronic diabetic foot ulcers in the <em>International Wound Journal</em>.</li><li>In the intent-to-treat group, 70% of patients receiving weekly dHUC allograft achieved complete healing by week 12 compared to 48% of those receiving standard-of-care &#40;SOC&#41; treatment for 12 weeks (p=0.0089).</li><li>81% of patients completing the study per-protocol treated with dHUC experienced complete healing by week 12 versus 54% for SOC (p=0.0013).</li><li>The company currently markets dHUC under the brand names EpiCord and AmnioCord.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392706\" data-linked=\"MiMedx up 6% premarket on positive data on dHUC in diabetic foot ulcers\" data-tweet=\"$MDXG - MiMedx up 6% premarket on positive data on dHUC in diabetic foot ulcers https://seekingalpha.com/news/3392706-mimedx-up-6-premarket-on-positive-data-on-dhuc-in-diabetic-foot-ulcers?source=tweet\" data-url=\"https://seekingalpha.com/news/3392706-mimedx-up-6-premarket-on-positive-data-on-dhuc-in-diabetic-foot-ulcers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392702\" data-ts=\"1537879023\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XOXO\" target=\"_blank\">XOXO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392702-xo-group-going-private-in-933-buyout-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XO Group going private in $933 buyout deal</a></h4><ul>     <li>XO Group (NYSE:<a href='https://seekingalpha.com/symbol/XOXO' title='XO Group Inc.'>XOXO</a>) <font color='green'>+23.2</font>% pre-market after saying it will <a href=\"https://seekingalpha.com/pr/17279620-xo-group-inc-become-privately-held-company-merge-weddingwire-accelerating-growth-within\" target=\"_blank\">sell itself</a> to wedding planning firm WeddingWire in a deal valued at $933M that will take it private.</li>     <li>Under the deal terms, XO shareholders will receive $35/share in cash, representing a 27% premium to Monday's closing price of $27.64.</li>     <li>The combined company will be owned by the Permira Funds and Spectrum Equity, the current investors in WeddingWire.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392702\" data-linked=\"XO Group going private in $933 buyout deal\" data-tweet=\"$XOXO - XO Group going private in $933 buyout deal https://seekingalpha.com/news/3392702-xo-group-going-private-in-933-buyout-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3392702-xo-group-going-private-in-933-buyout-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392701\" data-ts=\"1537878909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBL\" target=\"_blank\">JBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392701-jabilplus-3-on-q4-beats-in-line-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jabil +3% on Q4 beats, in-line guide</a></h4><ul><li>        Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>)&nbsp;<font color='green'>gains 3.1%</font>&nbsp;premarket on Q4 results that beat estimates with a 15% Y/Y revenue growth. In-line Q1 guidance has revenue from $5.8B to $6.4B (consensus: $5.91B) and EPS of $0.79 to $0.99 (consensus: $0.88).</li><li>               Revenue breakdown: Electronics Manufacturing, $3.36B (consensus: $3.25B); Diversified Manufacturing, $2.44B (consensus: $2.16B).&nbsp;</li><li>                  Gross margin was 7.66% and non-GAAP operating margin came in at 3.68%. &nbsp;   </li><li>                  Earnings call started at 8:30 AM ET with a webcast available <a href=\"http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.jabil.com&amp;esheet=51872012&amp;newsitemid=20180925005300&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestors.jabil.com&amp;index=1&amp;md5=f8036b3ffcf6dd33fb719b1fa2839ba6\" target=\"_blank\">here.</a>    </li><li>               <a href=\"https://seekingalpha.com/pr/17279607-jabil-delivers-another-strong-fiscal-year\" target=\"_blank\">Press release</a>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392677-jabil-beats-0_02-beats-revenue\" target=\"_blank\">Jabil beats by $0.02, beats on revenue</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392701\" data-linked=\"Jabil +3% on Q4 beats, in-line guide\" data-tweet=\"$JBL - Jabil +3% on Q4 beats, in-line guide https://seekingalpha.com/news/3392701-jabilplus-3-on-q4-beats-in-line-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3392701-jabilplus-3-on-q4-beats-in-line-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392699\" data-ts=\"1537878694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PINC\" target=\"_blank\">PINC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392699-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Premier (NASDAQ:<a href='https://seekingalpha.com/symbol/PINC' title='Premier, Inc.'>PINC</a>) initiated with Overweight rating and $50 (14% upside) price target at Barclays.</li><li>Agios Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AGIO' title='Agios Pharmaceuticals, Inc.'>AGIO</a>) initiated with Market Perform rating and $80 (6% upside) price target at Leerink Partners.</li><li>BeiGene (NASDAQ:<a href='https://seekingalpha.com/symbol/BGNE' title='BeiGene'>BGNE</a>) initiated with Outperform rating and $215 (30% upside) price target at Leerink.</li><li>Cambrex (NYSE:<a href='https://seekingalpha.com/symbol/CBM' title='Cambrex Corporation'>CBM</a>) initiated with Buy rating and $75.50 (20% upside) price target at Jefferies.</li><li>Clovis Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a>) initiated with Market Perform rating at Leerink.</li><li>Incyte (NASDAQ:<a href='https://seekingalpha.com/symbol/INCY' title='Incyte Corporation'>INCY</a>) initiated with Market Perform rating and $78 (17% upside) price target at Leerink.</li><li>Seattle Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/SGEN' title='Seattle Genetics, Inc.'>SGEN</a>) initiated with Outperform rating and $101 (29% upside) price target at Leerink.</li><li>Amarin (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a>) price target raised to $15 (21% upside) at Jefferies and $17 at Citigroup after successful REDUCE-IT study. Shares down&nbsp;<font color='red'>3%</font>&nbsp;premarket after yesterday's four-fold jump.</li><li>NextGen Healthcare (NASDAQ:<a href='https://seekingalpha.com/symbol/NXGN' title='NextGen Healthcare Inc'>NXGN</a>) reinstated with Underperform rating and $17 (16% downside risk) price target at RBC.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392699\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$PINC $PINC $AGIO - Premarket analyst action - healthcare https://seekingalpha.com/news/3392699-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3392699-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392692\" data-ts=\"1537878007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADI\" target=\"_blank\">ADI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392692-raymond-james-tech-downgrades-include-intel-analog-devices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raymond James tech downgrades include Intel, Analog Devices</a></h4><ul><li>        Raymond James downgrades a slate of tech names.</li><li>               Moving from Outperform to Market Perform: Analog Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/ADI' title='Analog Devices Inc.'>ADI</a>), Microchip (NASDAQ:<a href='https://seekingalpha.com/symbol/MCHP' title='Microchip Technology Incorporated'>MCHP</a>), ON Semiconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/ON' title='ON Semiconductor Corporation'>ON</a>).&nbsp;</li><li>                  Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) was downgraded from Market Perform to Underperform.    </li><li>                  Monolithic Power (NASDAQ:<a href='https://seekingalpha.com/symbol/MPWR' title='Monolithic Power Systems, Inc.'>MPWR</a>) was downgraded to Outperform from Strong Buy with the target reiterated at $160. &nbsp;   </li><li>               Source: StreetAccount.&nbsp;</li><li>ADI shares are&nbsp;<font color='red'>down 2.2%</font>&nbsp;premarket to $92.90.&nbsp;</li><li>ON shares are&nbsp;<font color='red'>down 1.2%</font>&nbsp;to $18.87.&nbsp;</li><li>INTC is&nbsp;<font color='red'>down 1.1%</font>&nbsp;to $46.40.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392647-keybanc-starts-10-semi-names-sector-weight\" target=\"_blank\">KeyBanc starts 10 semi names at Sector Weight</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392692\" data-linked=\"Raymond James tech downgrades include Intel, Analog Devices\" data-tweet=\"$ADI $ADI $MCHP - Raymond James tech downgrades include Intel, Analog Devices https://seekingalpha.com/news/3392692-raymond-james-tech-downgrades-include-intel-analog-devices?source=tweet\" data-url=\"https://seekingalpha.com/news/3392692-raymond-james-tech-downgrades-include-intel-analog-devices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392688\" data-ts=\"1537877715\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBEV\" target=\"_blank\">NBEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392688-new-age-beverages-up-12-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Age Beverages up 12% premarket</a></h4><ul><li>New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) is up&nbsp;<font color='green'>12%</font>&nbsp;premarket on robust volume as speculators move back in, apparently stoked by the jump in Tilray (<font color='green'>+16%</font>) after it announced that it will supply medical cannabis in Australia.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392662-tilray-20_6-percent-medical-cannabis-supply-australia\" target=\"_blank\">Tilray up 20.6% on medical cannabis supply to Australia</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392688\" data-linked=\"New Age Beverages up 12% premarket\" data-tweet=\"$NBEV - New Age Beverages up 12% premarket https://seekingalpha.com/news/3392688-new-age-beverages-up-12-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3392688-new-age-beverages-up-12-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392683\" data-ts=\"1537877287\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVAX\" target=\"_blank\">NVAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392683-novavax-up-3-premarket-on-launch-of-mid-stage-study-of-nanoflu-in-older-adults\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novavax up 3% premarket on launch of mid-stage study of NanoFlu in older adults</a></h4><ul><li>Novavax (NASDAQ:<a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a>) is up&nbsp;<font color='green'>3%</font>&nbsp;premarket on light volume on the heels of the <a href=\"https://seekingalpha.com/pr/17279485-novavax-initiates-phase-2-clinical-trial-nanoflu-older-adults\" target=\"_blank\">initiation </a>of a Phase 2 dose and formulation confirmation study evaluating NanoFlu in older adults.</li><li>The trial will assess different doses and formulations of NanoFlu, adjuvanted and unadjuvanted, in ~1,375 healthy older Americans. Topline data should be available in Q1 2019.</li><li>The results will inform on the design of a pivotal Phase 3 trial.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392683\" data-linked=\"Novavax up 3% premarket on launch of mid-stage study of NanoFlu in older adults\" data-tweet=\"$NVAX - Novavax up 3% premarket on launch of mid-stage study of NanoFlu in older adults https://seekingalpha.com/news/3392683-novavax-up-3-premarket-on-launch-of-mid-stage-study-of-nanoflu-in-older-adults?source=tweet\" data-url=\"https://seekingalpha.com/news/3392683-novavax-up-3-premarket-on-launch-of-mid-stage-study-of-nanoflu-in-older-adults\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392678\" data-ts=\"1537877024\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBEV\" target=\"_blank\">NBEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392678-another-volatile-day-setting-up-for-new-age-beverages\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Another volatile day setting up for New Age Beverages</a></h4><ul> <li>New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) is volatile again as the cannabis-beverage connection makes the stock a new favorite plaything of traders.</li> <li>SA contributor <a href=\"https://seekingalpha.com/article/4208004-road-cbd-infused-beverages-may-longer-harder-investors-anticipate\" target=\"_blank\">Altitrade Partners</a> explained yesterday why the CBD-infused beverage idea may be harder to pull off than investors realize.</li><li>Shares of NBEV are <font color='green'>up 16.2%</font> to $4.60 in premarket action.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3392678\" data-linked=\"Another volatile day setting up for New Age Beverages\" data-tweet=\"$NBEV - Another volatile day setting up for New Age Beverages https://seekingalpha.com/news/3392678-another-volatile-day-setting-up-for-new-age-beverages?source=tweet\" data-url=\"https://seekingalpha.com/news/3392678-another-volatile-day-setting-up-for-new-age-beverages\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392677\" data-ts=\"1537876879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBL\" target=\"_blank\">JBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392677-jabil-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jabil beats by $0.02, beats on revenue</a></h4><ul><li>Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>): Q4 Non-GAAP EPS of $0.70 <span style=\"color:green\">beats by $0.02</span>; GAAP EPS of -$0.34.</li><li>Revenue of $5.77B (+14.9% Y/Y) <font color='green'>beats by $340M</font>.</li><li>Shares <font color='green'>+4.1%</font> PM.</li><li><a href='https://seekingalpha.com/pr/17279607-jabil-delivers-another-strong-fiscal-year'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3392677\" data-linked=\"Jabil beats by $0.02, beats on revenue\" data-tweet=\"$JBL - Jabil beats by $0.02, beats on revenue https://seekingalpha.com/news/3392677-jabil-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3392677-jabil-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392674\" data-ts=\"1537876770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRON\" target=\"_blank\">CRON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392674-tilray-leading-pot-stocks-higher-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tilray leading pot stocks higher premarket</a></h4><ul><li>Cronos Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a>) and Canopy Growth (NYSE:<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>) are up&nbsp;<font color='green'>5%</font>&nbsp;and&nbsp;<font color='green'>4%</font>, respectively, premarket benefiting from buying in Tilray (<font color='green'>+20%</font>).</li><li>Selected tickers: <a href='https://seekingalpha.com/symbol/MJNA' title='Medical Marijuana, Inc.'>OTCPK:MJNA</a>, ACBFF, <a href='https://seekingalpha.com/symbol/GWPH' title='GW Pharmaceuticals plc'>GWPH</a>, <a href='https://seekingalpha.com/symbol/PHOT' title='Growlife Inc.'>OTCQB:PHOT</a>, <a href='https://seekingalpha.com/symbol/CBIS' title='Cannabis Science, Inc.'>OTCPK:CBIS</a>, APHQF, <a href='https://seekingalpha.com/symbol/TRTC' title='Terra Tech Corp.'>OTCQX:TRTC</a>, <a href='https://seekingalpha.com/symbol/CANN' title='General Cannabis Corp.'>OTCQX:CANN</a>, <a href='https://seekingalpha.com/symbol/ERBB' title='American Green, Inc.'>OTCPK:ERBB</a>, <a href='https://seekingalpha.com/symbol/GRNH' title='GreenGro Technologies, Inc.'>OTCPK:GRNH</a>, <a href='https://seekingalpha.com/symbol/PMCB' title='PharmaCyte Biotech, Inc.'>OTCQB:PMCB</a>, <a href='https://seekingalpha.com/symbol/CVSI' title='CV Sciences, Inc.'>OTCQB:CVSI</a>, <a href='https://seekingalpha.com/symbol/FITX' title='Creative Edge Nutrition, Inc.'>OTC:FITX</a>, <a href='https://seekingalpha.com/symbol/MJ' title='ETFMG Alternative Harvest ETF'>MJ</a>, <a href='https://seekingalpha.com/symbol/HEMP' title='Hemp, Inc.'>OTCPK:HEMP</a>, <a href='https://seekingalpha.com/symbol/CBDS' title='Cannabis Sativa, Inc.'>OTCQB:CBDS</a>, <a href='https://seekingalpha.com/symbol/BLOZF' title='Cannabix Technologies Inc.'>OTCPK:BLOZF</a>, <a href='https://seekingalpha.com/symbol/KSHB' title='KushCo Holdings, Inc.'>OTCQB:KSHB</a>, <a href='https://seekingalpha.com/symbol/MSRT' title='MassRoots, Inc.'>OTCQB:MSRT</a>, <a href='https://seekingalpha.com/symbol/SPRWF' title='Supreme Cannabis Co Inc.'>OTCQX:SPRWF</a>, <a href='https://seekingalpha.com/symbol/AGTK' title='Agritek Holdings, Inc.'>OTCPK:AGTK</a>, <a href='https://seekingalpha.com/symbol/AMMJ' title='American Cannabis Company, Inc.'>OTCPK:AMMJ</a>, <a href='https://seekingalpha.com/symbol/VAPE' title='Vape Holdings, Inc.'>OTCPK:VAPE</a>, HYYDF, <a href='https://seekingalpha.com/symbol/GBLX' title='GB Sciences, Inc.'>OTCQB:GBLX</a>, <a href='https://seekingalpha.com/symbol/AERO' title='Aero Grow International, Inc.'>OTCQB:AERO</a>, <a href='https://seekingalpha.com/symbol/MCOA' title='Marijuana Company of America, Inc.'>OTCQB:MCOA</a>, <a href='https://seekingalpha.com/symbol/HMLSF' title='Horizons Marijuana Life Sciences Index ETF'>OTC:HMLSF</a>, <a href='https://seekingalpha.com/symbol/CNAB' title='United Cannabis Corp.'>OTCQB:CNAB</a>, <a href='https://seekingalpha.com/symbol/FSPM' title='Fusion Pharm, Inc.'>OTC:FSPM</a>, <a href='https://seekingalpha.com/symbol/EAPH' title='Easton Pharmaceuticals, Inc.'>OTCPK:EAPH</a>, <a href='https://seekingalpha.com/symbol/SRNA' title='Surna Inc.'>OTCQB:SRNA</a>, <a href='https://seekingalpha.com/symbol/RMHB' title='Rocky Mountain High Brands, Inc.'>OTCQB:RMHB</a>, <a href='https://seekingalpha.com/symbol/PLPL' title='Plandai Biotechnology, Inc.'>OTCPK:PLPL</a>, <a href='https://seekingalpha.com/symbol/MNTR' title='Mentor Capital, Inc.'>OTCQX:MNTR</a>, <a href='https://seekingalpha.com/symbol/EDXC' title='ENDEXX Corp.'>OTCPK:EDXC</a>, <a href='https://seekingalpha.com/symbol/THCBF' title='THC Biomed International Ltd.'>OTCQX:THCBF</a>, <a href='https://seekingalpha.com/symbol/FSPM' title='Fusion Pharm, Inc.'>OTC:FSPM</a>, <a href='https://seekingalpha.com/symbol/EAPH' title='Easton Pharmaceuticals, Inc.'>OTCPK:EAPH</a>, <a href='https://seekingalpha.com/symbol/SRNA' title='Surna Inc.'>OTCQB:SRNA</a>, <a href='https://seekingalpha.com/symbol/RMHB' title='Rocky Mountain High Brands, Inc.'>OTCQB:RMHB</a>, <a href='https://seekingalpha.com/symbol/PLPL' title='Plandai Biotechnology, Inc.'>OTCPK:PLPL</a>, <a href='https://seekingalpha.com/symbol/MNTR' title='Mentor Capital, Inc.'>OTCQX:MNTR</a>, <a href='https://seekingalpha.com/symbol/EDXC' title='ENDEXX Corp.'>OTCPK:EDXC</a>, <a href='https://seekingalpha.com/symbol/THCBF' title='THC Biomed International Ltd.'>OTCQX:THCBF</a>, <a href='https://seekingalpha.com/symbol/KAYS' title='Kaya Holdings, Inc.'>OTCQB:KAYS</a>, <a href='https://seekingalpha.com/symbol/ENRT' title='Enertopia Corp'>OTCQB:ENRT</a>, <a href='https://seekingalpha.com/symbol/ENDO' title='Endocan CorporationA'>OTCPK:ENDO</a>, <a href='https://seekingalpha.com/symbol/NTRR' title='Neutra Corp.'>OTCQB:NTRR</a>, <a href='https://seekingalpha.com/symbol/REFG' title='Medical Cannabis Payment Solutions'>OTCPK:REFG</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3392662-tilray-20_6-percent-medical-cannabis-supply-australia\" target=\"_blank\">Tilray up 20.6% on medical cannabis supply to Australia</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392674\" data-linked=\"Tilray leading pot stocks higher premarket\" data-tweet=\"$CRON $CRON $CGC - Tilray leading pot stocks higher premarket https://seekingalpha.com/news/3392674-tilray-leading-pot-stocks-higher-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3392674-tilray-leading-pot-stocks-higher-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392673\" data-ts=\"1537876301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDS\" target=\"_blank\">FDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392673-factset-research-systemsminus-5-on-q4-misses-in-line-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FactSet Research Systems -5% on Q4 misses, in-line guide</a></h4><ul><li>        FactSet Research Systems (NYSE:<a href='https://seekingalpha.com/symbol/FDS' title='FactSet Research Systems Inc.'>FDS</a>)&nbsp;<font color='red'>drops 5.1%</font>&nbsp;premarket on Q4 results that missed EPS and revenue estimates. In-line FY19 guidance has revenue of $1.41B to $1.45B (consensus: $1.44B) and EPS of $9.45 to $9.65 (consensus: $9.61).</li><li>               Key metrics: ASV, $1.39B; Organic ASV, +$38.6M Q/Q; Adjusted operating margin, 31.3%; client count, +167 to 5,142; Users, +2,391 to 91.9K.&nbsp;</li><li>                  Earnings call is scheduled for 11 AM ET with a webcast available <a href=\"https://www.globenewswire.com/Tracker?data=YspW1YiuZTX0cc5tBAHY5da6tz-wXQh-ObyjZ2hePepJhNAR30SEHZwTewLQjcDG2BQ4D_TrsGIHBptuMJKDeL3i4HkJQaPMDZeGNsBktvKg__PphBuN7pC_W06cSDJNrOMoFraNvHxsPkfBzLP7Pw==\" target=\"_blank\">here</a>.    </li><li>               <a href=\"https://seekingalpha.com/pr/17279493-factset-reports-strong-revenue-eps-growth-fourth-quarter-2018\" target=\"_blank\">Press release</a>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392650-factset-research-systems-misses-0_01-misses-revenue\" target=\"_blank\">FactSet Research Systems misses by $0.01, misses on revenue</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392673\" data-linked=\"FactSet Research Systems -5% on Q4 misses, in-line guide\" data-tweet=\"$FDS - FactSet Research Systems -5% on Q4 misses, in-line guide https://seekingalpha.com/news/3392673-factset-research-systemsminus-5-on-q4-misses-in-line-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3392673-factset-research-systemsminus-5-on-q4-misses-in-line-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:51 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}